nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,days_since_update
NCT04320953,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-21,NA,NA,2020-04-15,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"March 16, 2020",Actual,2020-03-16,April 2020,2020-04-30,"April 9, 2020",Actual,2020-04-09,"March 26, 2020",Actual,2020-03-26,NA,Interventional,NA,,Non-contact Endoscopy at Covid-19 Outbreak,Non-contact Endoscopy at Covid-19 Outbreak,Completed,NA,N/A,5,Actual,Changhai Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:35:01Z,2021-02-01T12:35:01Z,311
NCT04720794,"ClinicalTrials.gov processed this data on January 29, 2021",2020-10-13,NA,NA,2021-01-22,2021-01-20,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-22,2021-01-26,Actual,"September 25, 2020",Actual,2020-09-25,January 2021,2021-01-31,"October 20, 2020",Actual,2020-10-20,"October 20, 2020",Actual,2020-10-20,NA,Interventional,NA,,A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion,A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit As Compared To The Hologic Panther Fusion SARS-CoV-2 RT-PCR Assay,Completed,NA,N/A,101,Actual,Lucira Health Inc,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-02-01T11:39:01Z,2021-02-01T11:39:01Z,29
NCT04719234,"ClinicalTrials.gov processed this data on January 29, 2021",2021-01-20,NA,NA,2021-01-21,2021-01-21,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-22,Actual,"June 15, 2020",Actual,2020-06-15,January 2021,2021-01-31,"December 1, 2020",Actual,2020-12-01,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,,Lung Ultrasonography in COVID-19 Pneumonia,Comparison of Lung Ultrasonography Findings With Chest Computerized Tomography Results in Corona virÃ¼s (COVID-19) Pneumonia,Completed,NA,N/A,60,Actual,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T11:39:12Z,2021-02-01T11:39:12Z,30
NCT04716647,"ClinicalTrials.gov processed this data on January 29, 2021",2021-01-18,NA,NA,2021-01-19,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-01-19,2021-01-20,Actual,"October 9, 2020",Actual,2020-10-09,January 2021,2021-01-31,"December 18, 2020",Actual,2020-12-18,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,,Feasibility of Ayurveda in Patients With Mild-to-Moderate COVID-19: A Community-Based Participatory Research,A Community-Based Participatory Research to Assess the Feasibility of Ayurveda Intervention in Patients With Mild-to-Moderate COVID-19,Completed,NA,N/A,28,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T11:39:30Z,2021-02-01T11:39:30Z,32
NCT04713878,"ClinicalTrials.gov processed this data on January 29, 2021",2021-01-09,NA,NA,2021-01-16,2021-01-15,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-01-16,2021-01-20,Actual,"May 8, 2020",Actual,2020-05-08,January 2021,2021-01-31,"July 15, 2020",Actual,2020-07-15,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,,Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia,A 8-Week Trial of Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia,Completed,NA,N/A,21,Actual,Kanuni Sultan Suleyman Training and Research Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T11:39:49Z,2021-02-01T11:39:49Z,35
NCT04713111,"ClinicalTrials.gov processed this data on January 29, 2021",2021-01-08,NA,NA,2021-01-14,2021-01-14,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-01-14,2021-01-19,Actual,"May 4, 2020",Actual,2020-05-04,January 2021,2021-01-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,,Stress and Recovery in Frontline COVID-19 Workers,Stress and Recovery in Frontline Healthcare COVID-19 Workers: A Feasibility Study Using Wearable and Smartphone Devices,Completed,NA,N/A,383,Actual,4YouandMe,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"Internal collaborative researchers will have access to all coded data during the full duration of the study. Consented participants' coded data will be available in the Synapse at Sage Bionetworks for selected researchers to access indefinitely, one year after study completion.","As coded study data will then exist among consenting participants in the Synapse at Sage Bionetworks in de-identified form, the electronic data files will be kept indefinitely. The Principal Investigator will be responsible for receipt and/or transmission of data as required.",NA,Yes,"Under the 4YouandMe open source model, we will make all data, findings, digital health applications and algorithms available in the public domain. Accordingly, de-identified data produced from this project will be shared broadly with qualified researchers (among participants who opt in) through Sage Bionetworks Synapse and will serve as an immense resource, reflecting a highly granular and high- dimensional map of physiological stress responses and knowledge surrounding inadvertent consequences of objective stress measurement. Only data from consenting participants will be shared through Sage Bionetworks Synapse. Additionally, Source code for the developed app will be made available as open source software on GitHub so it can be evolved for future work by others.",2021-02-01T11:39:55Z,2021-02-01T11:39:55Z,37
NCT04712045,"ClinicalTrials.gov processed this data on January 29, 2021",2021-01-11,NA,NA,2021-01-13,2021-01-13,2021-01-15,Actual,NA,NA,NA,NA,NA,NA,2021-01-13,2021-01-15,Actual,"August 1, 2020",Actual,2020-08-01,January 2021,2021-01-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Interventional,RUPERT,,Rational Use of Personal Protective Equipment During COVID-19 Pandemic,Rational Use of Personal Protective Equipment: a Randomised Trial and Quality Improvement Intervention During COVID-19 Pandemic,Completed,NA,N/A,67,Actual,University of Oxford,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T11:40:02Z,2021-02-01T11:40:02Z,38
NCT04707742,"ClinicalTrials.gov processed this data on January 29, 2021",2021-01-07,NA,NA,2021-01-12,2021-01-12,2021-01-13,Actual,NA,NA,NA,NA,NA,NA,2021-01-12,2021-01-13,Actual,"June 15, 2020",Actual,2020-06-15,January 2021,2021-01-31,"November 18, 2020",Actual,2020-11-18,"November 18, 2020",Actual,2020-11-18,NA,Interventional,BUCOSARS,,Antiseptic Mouth Rinses to Reduce Salivary Viral Load in COVID-19 Patients,Clinical Evaluation of Antiseptic Mouth Rinses to Reduce Salivary Viral Load of SARS-CoV-2 in COVID-19 Patients,Completed,NA,N/A,84,Actual,FundaciÃ³n para el Fomento de la InvestigaciÃ³n Sanitaria y BiomÃ©dica de la Comunitat Valenciana,,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T11:40:31Z,2021-02-01T11:40:31Z,39
NCT04705753,"ClinicalTrials.gov processed this data on January 29, 2021",2021-01-06,NA,NA,2021-01-11,2021-01-11,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-12,Actual,"April 1, 2020",Actual,2020-04-01,January 2021,2021-01-31,"October 15, 2020",Actual,2020-10-15,"October 15, 2020",Actual,2020-10-15,NA,Interventional,COVID-19-IAMA,,"Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients","Evaluation of the Clinical Outcomes and the Quality of Life of Patients Exhibiting Symptoms Characteristic of Viral Respiratory Infection (VRI), Including Infection by SARS-CoV-2 (COVID-19), and Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in These Patients and the People Cohabiting With Them Via an Open-label, Single-arm Trial",Completed,NA,Phase 2/Phase 3,20,Actual,University of Crete,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T11:40:48Z,2021-02-01T11:40:48Z,40
NCT04701710,"ClinicalTrials.gov processed this data on January 29, 2021",2021-01-07,NA,NA,2021-01-08,2021-01-07,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"October 15, 2020",Actual,2020-10-15,January 2021,2021-01-31,"December 31, 2020",Actual,2020-12-31,"December 18, 2020",Actual,2020-12-18,NA,Interventional,Ivercar-Tuc,,Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan,A Randomized Trial - Intensive Treatment Based in Ivermectin and Iota-carrageenan as Prophylaxis for Covid-19 In Healthcare Agents,Completed,NA,Phase 1/Phase 2,300,Actual,"Ministry of Public Health, Argentina",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,N/C,2021-02-01T11:41:15Z,2021-02-01T11:41:15Z,43
NCT04690920,"ClinicalTrials.gov processed this data on January 29, 2021",2020-12-19,NA,NA,2020-12-30,2020-12-30,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2020-12-30,2020-12-31,Actual,"July 23, 2020",Actual,2020-07-23,December 2020,2020-12-31,"December 10, 2020",Actual,2020-12-10,"December 10, 2020",Actual,2020-12-10,NA,Interventional,NA,,Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins,Theranostic Implication of Complimentary Medicines Against IL-6/Gp-130 in COVID-19.: An in Vitro and in Silco Approach,Completed,NA,N/A,200,Actual,University of Lahore,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,"statistical analysis, results",2021-02-01T11:42:34Z,2021-02-01T11:42:34Z,52
NCT04687488,"ClinicalTrials.gov processed this data on January 29, 2021",2020-12-03,NA,NA,2020-12-22,2020-12-22,2020-12-29,Actual,NA,NA,NA,NA,NA,NA,2020-12-22,2020-12-29,Actual,"July 23, 2020",Actual,2020-07-23,December 2020,2020-12-31,"November 9, 2020",Actual,2020-11-09,"November 9, 2020",Actual,2020-11-09,NA,Interventional,NA,,Aerosol and Droplet Dispersion During Gastrointestinal Motility Investigations,COVID-19: The Study of Aerosol Generation and Droplet Dispersion and Deposition During Naso-gastric Intubation for Gastrointestinal Motility Investigations,Completed,NA,N/A,15,Actual,Universitaire Ziekenhuizen Leuven,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T11:43:01Z,2021-02-01T11:43:01Z,60
NCT04337996,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-01,NA,NA,2021-01-25,2020-04-03,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-26,Actual,"July 13, 2020",Actual,2020-07-13,January 2021,2021-01-31,"January 13, 2021",Actual,2021-01-13,"January 13, 2021",Actual,2021-01-13,NA,Interventional,TRODVID-19,,Dynamic Evaluation of COVID-19 Diagnostic Tests,Dynamic Evaluation of COVID-19 Diagnostic Tests,Completed,NA,N/A,8,Actual,Tourcoing Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:32:16Z,2021-02-01T12:32:16Z,26
NCT04677270,"ClinicalTrials.gov processed this data on January 29, 2021",2020-12-18,NA,NA,2020-12-18,2020-12-18,2020-12-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-18,2020-12-21,Actual,"August 31, 2020",Actual,2020-08-31,December 2020,2020-12-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,COVIDPROBLEM,,Evaluation of Two Versions of a Digital Problem Solving Tool for the General Public Specific for the COVID-19 Pandemic,Evaluation of Two Versions of a Digital Problem Solving Tool for the General Public Specific for the COVID-19 Pandemic,Completed,NA,N/A,397,Actual,Karolinska Institutet,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T11:44:17Z,2021-02-01T11:44:17Z,64
NCT04668469,"ClinicalTrials.gov processed this data on January 29, 2021",2020-11-25,NA,NA,2020-12-11,2020-12-11,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-16,Actual,"June 8, 2020",Actual,2020-06-08,December 2020,2020-12-31,"October 30, 2020",Actual,2020-10-30,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,,Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic,Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic,Completed,NA,N/A,600,Actual,Benha University,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T11:45:26Z,2021-02-01T11:45:26Z,71
NCT04656626,"ClinicalTrials.gov processed this data on January 29, 2021",2020-12-04,NA,NA,2020-12-08,2020-12-04,2020-12-07,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-10,Actual,"July 7, 2020",Actual,2020-07-07,December 2020,2020-12-31,"September 5, 2020",Actual,2020-09-05,"July 21, 2020",Actual,2020-07-21,NA,Interventional,NA,,Brief Mindfulness Based Intervention to Improve Psychological Wellbeing,"Brief Mindfulness Based Intervention for Front-Line Medical Staff in the COVID19 Pandemic to Improve Psychological Wellbeing, a Randomized Controlled Multicenter Trial",Completed,NA,N/A,146,Actual,Imam Abdulrahman Bin Faisal University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T11:47:01Z,2021-02-01T11:47:01Z,74
NCT04652648,"ClinicalTrials.gov processed this data on January 29, 2021",2020-12-02,NA,NA,2020-12-02,2020-12-02,2020-12-03,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-03,Actual,"May 27, 2020",Actual,2020-05-27,December 2020,2020-12-31,"November 15, 2020",Actual,2020-11-15,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Completed,NA,Phase 4,54,Actual,Bryn Mawr Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T11:47:29Z,2021-02-01T11:47:29Z,80
NCT04646109,"ClinicalTrials.gov processed this data on January 29, 2021",2020-11-15,2020-12-03,NA,2021-01-25,2020-11-25,2020-11-27,Actual,2021-01-25,2021-01-27,Actual,NA,NA,NA,2021-01-25,2021-01-27,Actual,"May 11, 2020",Actual,2020-05-11,January 2021,2021-01-31,"September 2, 2020",Actual,2020-09-02,"September 2, 2020",Actual,2020-09-02,NA,Interventional,NA,"36 patients were included in the study group. But, 6 patients in the study group were excluded from the study and analysis because ivermectin treatments were terminated due to the detection of a mutation that impairs ivermectin metabolism. As a result, overall number of baseline participants in the study group was 30.",Ivermectin for Severe COVID-19 Management,The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management,Completed,NA,Phase 3,66,Actual,Afyonkarahisar Health Sciences University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T11:48:18Z,2021-02-01T11:48:18Z,26
NCT04645407,"ClinicalTrials.gov processed this data on January 29, 2021",2020-02-15,NA,NA,2020-11-25,2020-11-25,2020-11-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-27,Actual,"February 1, 2020",Actual,2020-02-01,November 2020,2020-11-30,"April 15, 2020",Actual,2020-04-15,"April 15, 2020",Actual,2020-04-15,NA,Interventional,NA,,Effects of Fuzheng Huayu Tablets on COVID-19,Efficacy of Fuzheng Huayu Tablets for Treating Pulmonary Inflammation in Patients With COVID-19: A Case-Control Study,Completed,NA,Phase 4,66,Actual,ShuGuang Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T11:48:23Z,2021-02-01T11:48:23Z,87
NCT04622891,"ClinicalTrials.gov processed this data on January 29, 2021",2020-11-06,NA,NA,2020-11-07,2020-11-07,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-07,2020-11-10,Actual,"April 1, 2020",Actual,2020-04-01,November 2020,2020-11-30,"July 30, 2020",Actual,2020-07-30,"July 30, 2020",Actual,2020-07-30,NA,Interventional,NA,,Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection,"Efficacy of Clarithromycin in Comparison to Azithromycin in Treatment of Mild COVID-19 Infection, Randomized Controlled Trial",Completed,NA,N/A,300,Actual,South Valley University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T11:51:22Z,2021-02-01T11:51:22Z,105
NCT04621903,"ClinicalTrials.gov processed this data on January 29, 2021",2020-11-06,NA,NA,2020-11-18,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-18,2020-11-19,Actual,"October 8, 2020",Actual,2020-10-08,November 2020,2020-11-30,"November 3, 2020",Actual,2020-11-03,"October 27, 2020",Actual,2020-10-27,NA,Interventional,NA,,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19: Community Based Participatory Research,Completed,NA,N/A,26,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T11:51:30Z,2021-02-01T11:51:30Z,94
NCT04475575,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-15,NA,NA,2020-07-16,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"April 6, 2020",Actual,2020-04-06,July 2020,2020-07-31,"July 1, 2020",Actual,2020-07-01,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,,Can the Electronic Nose Smell COVID-19 Antibodies?,Can the Electronic Nose Smell COVID-19 Antibodies? A Proof-of-principle Study,Completed,NA,N/A,222,Actual,Maastricht University Medical Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-02-01T12:11:19Z,2021-02-01T12:11:19Z,219
NCT04609969,"ClinicalTrials.gov processed this data on January 29, 2021",2020-10-28,NA,NA,2020-12-04,2020-10-28,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2020-12-04,2020-12-07,Actual,"October 13, 2020",Actual,2020-10-13,December 2020,2020-12-31,"October 17, 2020",Actual,2020-10-17,"October 17, 2020",Actual,2020-10-17,NA,Interventional,COVID-VIRO,,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test on Nasopharyngeal Specimens i,Completed,NA,N/A,200,Actual,Centre Hospitalier RÃ©gional d'OrlÃ©ans,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T11:53:11Z,2021-02-01T11:53:11Z,78
NCT04475562,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-15,NA,NA,2020-07-16,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"April 6, 2020",Actual,2020-04-06,July 2020,2020-07-31,"July 1, 2020",Actual,2020-07-01,"May 6, 2020",Actual,2020-05-06,NA,Interventional,NA,,Can the Electronic Nose Smell COVID-19?,Can the Electronic Nose Smell COVID-19? A Proof-of-principle Study,Completed,NA,N/A,219,Actual,Maastricht University Medical Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-02-01T12:11:19Z,2021-02-01T12:11:19Z,219
NCT04603729,"ClinicalTrials.gov processed this data on January 29, 2021",2020-10-21,NA,NA,2020-10-24,2020-10-24,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-24,2020-10-27,Actual,"May 30, 2020",Actual,2020-05-30,October 2020,2020-10-31,"July 1, 2020",Actual,2020-07-01,"June 30, 2020",Actual,2020-06-30,NA,Interventional,covid19,,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Completed,NA,Phase 3,100,Actual,Fatima Memorial Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,"patient name and medical record will be confidential, onle the principal investigator will have access to data. Results of study will be shared with other researchers",2021-02-01T11:54:04Z,2021-02-01T11:54:04Z,119
NCT04599959,"ClinicalTrials.gov processed this data on January 29, 2021",2020-10-22,NA,NA,2021-01-25,2020-10-22,2020-10-23,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-26,Actual,"October 26, 2020",Actual,2020-10-26,January 2021,2021-01-31,"January 20, 2021",Actual,2021-01-20,"January 20, 2021",Actual,2021-01-20,NA,Interventional,NA,,COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With SalivetteÂ® Cortisol for Viral RNA Sampling for RT-qPCR,"COVID-19 Tests: a Systematic Comparison of Viral RNA Test Sample Taking for RT-qPCR, in This Case With a Nasopharyngeal Swab or Saliva Collected With SalivetteÂ® Cortisol, to Diagnose SARS-CoV-2 Virus Infection",Completed,NA,N/A,144,Actual,Boehringer Ingelheim,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:
studies in products where Boehringer Ingelheim is not the license holder;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).
For more details refer to: http://trials.boehringer-ingelheim.com/",2021-02-01T11:54:31Z,2021-02-01T11:54:31Z,26
NCT04591600,"ClinicalTrials.gov processed this data on January 29, 2021",2020-10-15,NA,NA,2020-10-16,2020-10-16,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"July 1, 2020",Actual,2020-07-01,October 2020,2020-10-31,"October 14, 2020",Actual,2020-10-14,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,,Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients,"Controlled Randomized Clinical Trial on Using Ivermectin With Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq",Completed,NA,Phase 1/Phase 2,140,Actual,Alkarkh Health Directorate-Baghdad,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T11:55:41Z,2021-02-01T11:55:41Z,127
NCT04589117,"ClinicalTrials.gov processed this data on January 29, 2021",2020-10-12,NA,NA,2020-10-14,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"May 27, 2020",Actual,2020-05-27,October 2020,2020-10-31,"August 2, 2020",Actual,2020-08-02,"August 2, 2020",Actual,2020-08-02,NA,Interventional,NA,,Expressive Writing for COVID-19 Resilience for Parents,Expressive Writing for COVID-19 Resilience for Parents,Completed,NA,N/A,11,Actual,Duke University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T11:56:06Z,2021-02-01T11:56:06Z,129
NCT04589104,"ClinicalTrials.gov processed this data on January 29, 2021",2020-10-12,NA,NA,2020-10-14,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"May 26, 2020",Actual,2020-05-26,October 2020,2020-10-31,"August 17, 2020",Actual,2020-08-17,"August 17, 2020",Actual,2020-08-17,NA,Interventional,NA,,Expressive Writing for COVID-19 Resilience,Expressive Writing for COVID-19 Resilience,Completed,NA,N/A,63,Actual,Duke University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T11:56:06Z,2021-02-01T11:56:06Z,129
NCT04583189,"ClinicalTrials.gov processed this data on January 29, 2021",2020-10-01,NA,NA,2020-12-01,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-02,Actual,"October 1, 2020",Actual,2020-10-01,December 2020,2020-12-31,"November 25, 2020",Actual,2020-11-25,"November 25, 2020",Actual,2020-11-25,NA,Interventional,NA,,Evaluation of the Performance of the Covid-19 Ag BSS Rapid Antigenic Test in Symptomatic Children in a Pediatric Emergency Department,Evaluation Des Performances du Test Rapide antigÃ©nique Covid-19 Ag BSS Chez l'Enfant Symptomatique Dans un Service d'Urgences pÃ©diatriques,Completed,NA,N/A,500,Actual,Centre Hospitalier Intercommunal Creteil,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T11:56:53Z,2021-02-01T11:56:53Z,81
NCT04581291,"ClinicalTrials.gov processed this data on January 29, 2021",2020-10-04,NA,NA,2020-10-07,2020-10-07,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-07,2020-10-09,Actual,"January 1, 2020",Actual,2020-01-01,October 2020,2020-10-31,"October 1, 2020",Actual,2020-10-01,"June 1, 2020",Actual,2020-06-01,NA,Interventional,NA,,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,Completed,NA,N/A,30,Actual,Istanbul Gelisim University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T11:57:09Z,2021-02-01T11:57:09Z,136
NCT04577235,"ClinicalTrials.gov processed this data on January 29, 2021",2020-09-29,NA,NA,2020-10-05,2020-10-05,2020-10-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"June 5, 2020",Actual,2020-06-05,October 2020,2020-10-31,"September 5, 2020",Actual,2020-09-05,"August 5, 2020",Actual,2020-08-05,NA,Interventional,NA,,Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores.,Evaluation of the Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores of Patients With Severe COVID 19 Pneumonia in Intensive Care.,Completed,NA,N/A,29,Actual,Gaziosmanpasa Taksim Research and Education Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T11:57:38Z,2021-02-01T11:57:38Z,138
NCT04573270,"ClinicalTrials.gov processed this data on January 29, 2021",2020-09-23,NA,NA,2020-09-30,2020-09-30,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"April 24, 2020",Actual,2020-04-24,September 2020,2020-09-30,"September 1, 2020",Actual,2020-09-01,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,,Mesenchymal Stem Cells for the Treatment of COVID-19,A Pilot Phase Study Evaluating the Effects of a Single Mesenchymal Stem Cell Injection in Patients With Suspected or Confirmed COVID-19 Infection and Healthcare Providers Exposed to Coronavirus Patients,Completed,NA,Phase 1,40,Actual,Thomas Advanced Medical LLC,,4,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,Data will be blinded and password protected. Research publications will be produced for medical journals. Participating Investigators will have password protected access only.,2021-02-01T11:58:11Z,2021-02-01T11:58:11Z,143
NCT04573361,"ClinicalTrials.gov processed this data on January 29, 2021",2020-09-29,NA,NA,2020-09-30,2020-09-30,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"May 2, 2020",Actual,2020-05-02,September 2020,2020-09-30,"May 27, 2020",Actual,2020-05-27,"May 27, 2020",Actual,2020-05-27,NA,Interventional,NA,,Access to Chiropractic Care During the COVID-19 Healthcare Emergency in Spain,Access to Chiropractic Care During the State of Emergency Generated by the COVID-19 Pandemic in Spain: a Pragmatic Controlled Trial,Completed,NA,N/A,723,Actual,Real Centro Universitario Maria Cristina,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"All collected IPD will be shared, though a next phase of the study is being debated, which is why we are still undecided.",2021-02-01T11:58:10Z,2021-02-01T11:58:10Z,143
NCT04572399,"ClinicalTrials.gov processed this data on January 29, 2021",2020-09-28,NA,NA,2020-12-28,2020-09-29,2020-10-01,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-30,Actual,"October 30, 2020",Actual,2020-10-30,December 2020,2020-12-31,"December 28, 2020",Actual,2020-12-28,"December 28, 2020",Actual,2020-12-28,NA,Interventional,NA,,UVA Light Device to Treat COVID-19,Respiratory Application of a Novel Ultraviolet Light Delivery Device for Patients Infected With COVID-19: A Pilot Study,Completed,NA,N/A,5,Actual,Cedars-Sinai Medical Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-02-01T11:58:17Z,2021-02-01T11:58:17Z,54
NCT04569188,"ClinicalTrials.gov processed this data on January 29, 2021",2020-09-04,NA,NA,2020-09-30,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"May 15, 2020",Actual,2020-05-15,September 2020,2020-09-30,"September 3, 2020",Actual,2020-09-03,"August 15, 2020",Actual,2020-08-15,NA,Interventional,RESCUE,,Convalescent Plasma in COVID-19 Elderly Patients,Real-time Evaluation of Safety and Efficacy of Convalescent Plasma Units Transfused to Elderly Patients With COVID-19,Completed,NA,Phase 2,21,Actual,Azienda Socio Sanitaria Territoriale di Mantova,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T11:58:40Z,2021-02-01T11:58:40Z,143
NCT04568356,"ClinicalTrials.gov processed this data on January 29, 2021",2020-09-27,NA,NA,2020-10-16,2020-09-27,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"April 24, 2020",Actual,2020-04-24,October 2020,2020-10-31,"September 24, 2020",Actual,2020-09-24,"June 12, 2020",Actual,2020-06-12,NA,Interventional,NA,,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,"A Clinical Performance Evaluation of the SARS-COV-2 Direct Antigen Rapid Test ""DART""",Completed,NA,N/A,200,Actual,"E25Bio, Inc.",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,FALSE,NA,,One month after the USA-FDA approval date and for the duration of one year after the date of approval,"via email to: Irene Bosch, PhD at ibosch@e25bio.com",http://www.e25bio.com,Yes,"The sponsor E25Bio, Inc. is in agreement to share the outcome of this Clinical Trial. Because the device product has not been previously approved or cleared by FDA, we will be publicly posting not earlier than the date of FDA approval or clearance.",2021-02-01T11:58:48Z,2021-02-01T11:58:48Z,127
NCT04568525,"ClinicalTrials.gov processed this data on January 29, 2021",2020-09-23,NA,NA,2020-09-28,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"July 1, 2020",Actual,2020-07-01,September 2020,2020-09-30,"August 1, 2020",Actual,2020-08-01,"July 25, 2020",Actual,2020-07-25,NA,Interventional,NA,,Passive Microwave Radiometry (MWR) and AI for COVID-19 Complications Early Diagnostics of Lungs,Microwave Radiation for Early Diagnostics of Pneumonia in Patients With COVID-19,Completed,NA,N/A,195,Actual,Kyrgyz State Medical Academy,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T11:58:46Z,2021-02-01T11:58:46Z,145
NCT04567810,"ClinicalTrials.gov processed this data on January 29, 2021",2020-09-18,NA,NA,2020-12-18,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-12-18,2020-12-21,Actual,"September 18, 2020",Actual,2020-09-18,December 2020,2020-12-31,"December 14, 2020",Actual,2020-12-14,"December 14, 2020",Actual,2020-12-14,NA,Interventional,NA,,"Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)","A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single -Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY)",Completed,NA,Phase 1,48,Actual,Stanford University,,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-02-01T11:58:55Z,2021-02-01T11:58:55Z,64
NCT04563689,"ClinicalTrials.gov processed this data on January 29, 2021",2020-09-22,NA,NA,2020-11-19,2020-09-23,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-19,2020-11-20,Actual,"June 18, 2020",Actual,2020-06-18,September 2020,2020-09-30,"October 23, 2020",Actual,2020-10-23,"October 22, 2020",Actual,2020-10-22,NA,Interventional,NA,,Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients,Efecto de un Enjuague Bucal Con Clorhexidina al 0.12% y Cloruro de Cetil Piridinio al 0.05% en la Carga Viral en Saliva en Pacientes COVID-19 + Hospitalizados o Que Esten Recibiendo Cuidado mÃ©dico en Casa en Cali - 2020.,Completed,NA,N/A,23,Actual,Dentaid SL,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T11:59:26Z,2021-02-01T11:59:26Z,93
NCT04561219,"ClinicalTrials.gov processed this data on January 29, 2021",2020-09-22,NA,NA,2020-10-26,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-28,Actual,"April 19, 2020",Actual,2020-04-19,October 2020,2020-10-31,"October 2, 2020",Actual,2020-10-02,"October 2, 2020",Actual,2020-10-02,NA,Interventional,NA,,Nitazoxanide Therapy for Patients With COVID-19 Pneumonia,"Nitazoxanide for Moderate to Severe COVID-19 Pneumonia: a Multicenter, Randomized, Placebo-controlled, Double-Blind Clinical Trial",Completed,NA,Phase 2,500,Actual,Universidade Federal do Rio de Janeiro,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Available as soon as the editorial board of the journal accepting the manuscript requires.,Editorial board of the Journal accepting the manuscript.,NA,Yes,"The investigators plan on sharing all IPD that underlie results in a publication for editorial board, with cautious of not sharing confidential data.",2021-02-01T11:59:44Z,2021-02-01T11:59:44Z,117
NCT04558372,"ClinicalTrials.gov processed this data on January 29, 2021",2020-09-20,NA,NA,2020-12-28,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-29,Actual,"April 1, 2020",Actual,2020-04-01,December 2020,2020-12-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,,Genosvid Diagnostic Test for Early Detection of COVID-19,Genosvid Diagnostic Test for Early Detection of COVID-19: UGM Electronic-Nose Innovation for Indonesia,Completed,NA,N/A,1999,Actual,Gadjah Mada University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:00:15Z,2021-02-01T12:00:15Z,54
NCT04557605,"ClinicalTrials.gov processed this data on January 29, 2021",2020-09-09,NA,NA,2020-10-16,2020-09-15,2020-09-21,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-20,Actual,"September 14, 2020",Actual,2020-09-14,October 2020,2020-10-31,"October 15, 2020",Actual,2020-10-15,"October 15, 2020",Actual,2020-10-15,NA,Interventional,NA,,Effects of a Face Mask on Oxygenation During Exercise,The Effects of Wearing a Face Mask During COVID-19 on Blood and Muscle Oxygenation While Performing Exercise,Completed,NA,N/A,14,Actual,University of Saskatchewan,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:00:20Z,2021-02-01T12:00:20Z,127
NCT04555005,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-11,NA,NA,2020-09-17,2020-09-17,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-17,2020-09-18,Actual,"March 10, 2020",Actual,2020-03-10,March 2020,2020-03-31,"April 26, 2020",Actual,2020-04-26,"April 26, 2020",Actual,2020-04-26,NA,Interventional,NA,,Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19,"Implementation of a Mindfulness-based Crisis Intervention for Frontline Healthcare Workers During the COVID-19 Outbreak in a Public General Hospital in Madrid, Spain",Completed,NA,N/A,1000,Actual,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:00:40Z,2021-02-01T12:00:40Z,156
NCT04551781,"ClinicalTrials.gov processed this data on January 29, 2021",2020-09-13,NA,NA,2020-09-14,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2020-09-14,2020-09-16,Actual,"April 1, 2020",Actual,2020-04-01,September 2020,2020-09-30,"July 30, 2020",Actual,2020-07-30,"July 30, 2020",Actual,2020-07-30,NA,Interventional,NA,,Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis,Short Term Low Dose Corticosteroids for Management of Post Covid-19 Pulmonary Fibrosis,Completed,NA,N/A,450,Actual,South Valley University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:01:07Z,2021-02-01T12:01:07Z,159
NCT04552483,"ClinicalTrials.gov processed this data on January 29, 2021",2020-09-09,NA,NA,2020-11-01,2020-09-15,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2020-11-01,2020-11-03,Actual,"June 8, 2020",Actual,2020-06-08,November 2020,2020-11-30,"September 5, 2020",Actual,2020-09-05,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,,Effects of Early Use of Nitazoxanide in Patients With COVID-19,Effects of Nitazoxanide Administration to Patients in the Initial Phase of COVID-19,Completed,NA,Phase 2,392,Actual,Universidade Federal do Rio de Janeiro,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Available as soon as the editorial board of the journal accepting the manuscript requires.,Editorial board of the Journal accepting the manuscript.,NA,Yes,"The investigators plan on sharing all IPD that underlie results in a publication for editorial board, with cautious of not sharing confidential data.",2021-02-01T12:01:02Z,2021-02-01T12:01:02Z,111
NCT04550325,"ClinicalTrials.gov processed this data on January 29, 2021",2020-09-10,NA,NA,2021-01-04,2020-09-13,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-01-04,2021-01-05,Actual,"August 5, 2020",Actual,2020-08-05,January 2021,2021-01-31,"November 26, 2020",Actual,2020-11-26,"November 26, 2020",Actual,2020-11-26,NA,Interventional,NA,,"Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19","A Phase 1/2 Open Label, Multicenter, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients With Pneumonia",Completed,NA,Phase 1/Phase 2,12,Actual,"Kamada, Ltd.",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:01:17Z,2021-02-01T12:01:17Z,47
NCT04548544,"ClinicalTrials.gov processed this data on January 29, 2021",2020-09-11,NA,NA,2020-09-11,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2020-09-11,2020-09-14,Actual,"October 18, 2019",Actual,2019-10-18,September 2020,2020-09-30,"May 20, 2020",Actual,2020-05-20,"May 20, 2020",Actual,2020-05-20,NA,Interventional,NA,,A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During COVID-19,A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During the COVID-19 Pandemic,Completed,NA,N/A,21,Actual,"University of California, San Francisco",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:01:30Z,2021-02-01T12:01:30Z,162
NCT04542941,"ClinicalTrials.gov processed this data on January 29, 2021",2020-08-31,NA,NA,2021-01-13,2020-09-07,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-01-13,2021-01-15,Actual,"June 16, 2020",Actual,2020-06-16,January 2021,2021-01-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,COVIDIT,,Assessment of Safety and Efficacy of CCP,Assessment of Safety and Efficacy of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Adults in Uganda; A Randomised Controlled Trial,Completed,NA,N/A,136,Actual,Makerere University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Arrangments to enable sharing of de-identified data will be instituted by the research team.,2021-02-01T12:02:18Z,2021-02-01T12:02:18Z,38
NCT04542694,"ClinicalTrials.gov processed this data on January 29, 2021",2020-09-04,2020-10-11,NA,2020-11-03,2020-09-04,2020-09-09,Actual,2020-11-03,2020-11-05,Actual,NA,NA,NA,2020-11-03,2020-11-05,Actual,"May 21, 2020",Actual,2020-05-21,November 2020,2020-11-30,"August 20, 2020",Actual,2020-08-20,"August 10, 2020",Actual,2020-08-10,NA,Interventional,NA,,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,"Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of Areplivir Film-coated Tablets (PROMOMED RUS LLC, Russia) in Patients Hospitalized With COVID-19",Completed,NA,Phase 3,200,Actual,"Promomed, LLC",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:02:19Z,2021-02-01T12:02:19Z,109
NCT04542876,"ClinicalTrials.gov processed this data on January 29, 2021",2020-09-08,NA,NA,2020-09-08,2020-09-08,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-09,Actual,"May 1, 2020",Actual,2020-05-01,September 2020,2020-09-30,"August 18, 2020",Actual,2020-08-18,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection: An Open Label Feasibility Study,Completed,NA,N/A,46,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:02:18Z,2021-02-01T12:02:18Z,165
NCT04536441,"ClinicalTrials.gov processed this data on January 29, 2021",2020-08-26,NA,NA,2020-09-01,2020-09-01,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-02,Actual,"April 1, 2020",Actual,2020-04-01,September 2020,2020-09-30,"June 30, 2020",Actual,2020-06-30,"May 30, 2020",Actual,2020-05-30,NA,Interventional,NA,,Ultra-brief Online Mindfulness-based Intervention During COVID-19 Movement Control Order,Effects of an Ultra-brief Online Mindfulness-based Intervention on Mental Health During the Coronavirus Disease (COVID-19) Outbreak in Malaysia: A Randomised Controlled Trial,Completed,NA,N/A,161,Actual,Universiti Tunku Abdul Rahman,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"The data will be become available once the study is being published, for 5 years.",The data will be made available upon request to the corresponding author.,NA,Yes,NA,2021-02-01T12:03:13Z,2021-02-01T12:03:13Z,172
NCT04535856,"ClinicalTrials.gov processed this data on January 29, 2021",2020-08-28,NA,NA,2021-01-25,2020-08-31,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"November 14, 2020",Actual,2020-11-14,January 2021,2021-01-31,"January 14, 2021",Actual,2021-01-14,"January 14, 2021",Actual,2021-01-14,NA,Interventional,DW-MSC,,Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,"Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients: Randomized, Double-blind, and Placebo-controlled",Completed,NA,Phase 1,9,Actual,Ina-Respond,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:03:18Z,2021-02-01T12:03:18Z,26
NCT04530422,"ClinicalTrials.gov processed this data on January 29, 2021",2020-08-26,NA,NA,2020-08-27,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-27,2020-08-28,Actual,"April 15, 2020",Actual,2020-04-15,August 2020,2020-08-31,"July 23, 2020",Actual,2020-07-23,"July 8, 2020",Actual,2020-07-08,NA,Interventional,NA,,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Completed,NA,Phase 3,250,Actual,Almaza Military Fever Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T12:04:04Z,2021-02-01T12:04:04Z,177
NCT04530357,"ClinicalTrials.gov processed this data on January 29, 2021",2020-08-26,NA,NA,2020-12-22,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-12-22,2020-12-24,Actual,"September 19, 2020",Actual,2020-09-19,October 2020,2020-10-31,"November 30, 2020",Actual,2020-11-30,"November 25, 2020",Actual,2020-11-25,NA,Interventional,NA,,"Reactogenicity, Safety and Immunogenicity of QazCovid-inÂ® COVID-19 Vaccine","Randomized, Blind, Placebo-controlled Phase- i Study and Randomized, Open Phase Phase-ii Study of QAZCOVID-INÂ®- COVID-19 Inactivated Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder",Completed,NA,Phase 1/Phase 2,244,Actual,Research Institute for Biological Safety Problems,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:04:04Z,2021-02-01T12:04:04Z,60
NCT04527562,"ClinicalTrials.gov processed this data on January 29, 2021",2020-08-25,NA,NA,2021-01-07,2020-08-25,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-11,Actual,"July 14, 2020",Actual,2020-07-14,January 2021,2021-01-31,"December 10, 2020",Actual,2020-12-10,"November 15, 2020",Actual,2020-11-15,NA,Interventional,COLCOVIDBD,,Colchicine in Moderate Symptomatic COVID-19 Patients,"Colchicine in Moderate Symptomatic COVID-19 Patients: Double Blind, Randomized, Placebo Controlled Trial to Observe the Efficacy",Completed,NA,N/A,299,Actual,Dhaka Medical College,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T12:04:24Z,2021-02-01T12:04:24Z,44
NCT04525742,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-28,NA,NA,2020-10-31,2020-08-23,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2020-10-31,2020-11-03,Actual,"July 5, 2020",Actual,2020-07-05,October 2020,2020-10-31,"September 15, 2020",Actual,2020-09-15,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,,COVID-19 Pandemic and Parents of Disabled Children,COVID-19 Pandemic From the Perspective of Parents of Disabled Children,Completed,NA,N/A,309,Actual,Gaziosmanpasa Taksim Research and Education Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Research is planned to bu conducted between June 15 th and July 15 th 2020. After 15 th of July in 1 week coming statistical analysis will be finished and than in 3 weeks article will be written,In necessary cases colleced data from the research will be shared with the local ethical committe,NA,Yes,Study protocol was established by Berrin Huner and Ebru Yilmaz YalcÄ±nkaya Statistical analysis (Power analysis) was established by Ozden Ozyemisci Taskiran Informed consent was written by Berrin Huner,2021-02-01T12:04:37Z,2021-02-01T12:04:37Z,112
NCT04523831,"ClinicalTrials.gov processed this data on January 29, 2021",2020-08-19,2020-09-30,NA,2020-10-07,2020-08-20,2020-08-24,Actual,2020-10-07,2020-10-09,Actual,NA,NA,NA,2020-10-07,2020-10-09,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,"September 10, 2020",Actual,2020-09-10,"August 22, 2020",Actual,2020-08-22,NA,Interventional,NA,We followed intention to treat analysis; SPSS (Statistical Package for Social Sciences) version 20 was used to analyze data. To compare mean of the two group chi square test was done.,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care,Completed,NA,Phase 3,400,Actual,Dhaka Medical College,"We followed up the patients by telephonic (video) interview, which has some inherent drawback for the study. we could not assess viral clearance directly. Only single dose regimen was used. Efficacy might higher if the different regimen would use.",2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,September 2020 to December 2020,Person who are investigating covid-19 in various aspects,NA,Yes,"Patients age, sex, Date of covid positive report, Symtoms,Date of covid negative report, post covid symptoms, time to recover.",2021-02-01T12:04:55Z,2021-02-01T12:04:55Z,136
NCT04519385,"ClinicalTrials.gov processed this data on January 29, 2021",2020-08-17,NA,NA,2020-08-21,2020-08-17,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-21,2020-08-25,Actual,"March 1, 2020",Actual,2020-03-01,August 2020,2020-08-31,"August 5, 2020",Actual,2020-08-05,"July 1, 2020",Actual,2020-07-01,NA,Interventional,NA,,Toclizumam Versus Dexamethasone in Severe Covid-19 Cases,Toclizumam Versus Dexamethasone in Severe Covid-19 Cases,Completed,NA,N/A,69,Actual,South Valley University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:05:30Z,2021-02-01T12:05:30Z,183
NCT04512027,"ClinicalTrials.gov processed this data on January 29, 2021",2020-08-11,NA,NA,2020-10-16,2020-08-12,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"September 15, 2020",Actual,2020-09-15,October 2020,2020-10-31,"October 16, 2020",Actual,2020-10-16,"September 19, 2020",Actual,2020-09-19,NA,Interventional,Prolectin-M,,Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.,"Effect of Prolectin-M; a (1-6)-Alpha-D-Mannopyranose on SarsCoV2 Viral Copy Numbers: A Proof of Concept, Open Label Randomized Controlled Trial",Completed,NA,N/A,10,Actual,Composite Interceptive Med Science,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:06:32Z,2021-02-01T12:06:32Z,127
NCT04500067,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-15,NA,NA,2020-10-12,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-12,2020-10-14,Actual,"May 7, 2020",Actual,2020-05-07,October 2020,2020-10-31,"September 15, 2020",Actual,2020-09-15,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,,"Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment","An Open-label Multicenter Randomized Trial to Evaluate the Efficacy of Bioven, Manufactured by Biopharma Plasma, LLC, in Complex Therapy of Patients With Pneumonia Induced by COVID-19 / SARS-CoV-2",Completed,NA,Phase 3,76,Actual,Biopharma Plasma LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,After trial result publication 3 months later,"For specialists in medicine, pharmacy, scientists",NA,Yes,"After completion of the trial, results will be published. Access to parts CSR planned after the release of scientific publications",2021-02-01T12:08:07Z,2021-02-01T12:08:07Z,131
NCT04498936,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-14,NA,NA,2020-11-10,2020-08-03,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"July 15, 2020",Actual,2020-07-15,November 2020,2020-11-30,"October 30, 2020",Actual,2020-10-30,"October 30, 2020",Actual,2020-10-30,NA,Interventional,NA,,Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19,"Efficacy of Adding Sofosbuvir/Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19: A Randomized Controlled Trial",Completed,NA,Phase 4,240,Actual,Assiut University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T12:08:14Z,2021-02-01T12:08:14Z,102
NCT04497623,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-27,NA,NA,2020-09-22,2020-08-01,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-24,Actual,"July 28, 2020",Actual,2020-07-28,September 2020,2020-09-30,"September 20, 2020",Actual,2020-09-20,"August 13, 2020",Actual,2020-08-13,NA,Interventional,SabanaHerons,,"Clinical Evaluation of Ventilador Innovation Product in Colombia in the SARS COVID 19 Pandemic, Unisabana Herons.","Clinical Evaluation of Ventilator Innovation Product in Colombia in the SARS Pandemic Covid 19, Unisabana Herons - A Cohort Study - Phase 1",Completed,NA,N/A,5,Actual,FundaciÃ³n Neumologica Colombiana,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,The clinical and ventilatory data of the patients will be entered into an anonymized database hosted on the RedCap platform with which the University of La Sabana has an agreement.,2021-02-01T12:08:24Z,2021-02-01T12:08:24Z,151
NCT04494204,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-28,NA,NA,2020-12-19,2020-07-30,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2020-12-19,2020-12-22,Actual,"August 7, 2020",Actual,2020-08-07,December 2020,2020-12-31,"December 20, 2020",Actual,2020-12-20,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,,Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients,"An Open Label, Multicenter, Randomized, Controlled, Clinical Study to Evaluate the Efficacy and Safety of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets Compared With Standard Treatment Protocol in the Treatment of Mild to Moderate COVID-19 Patients.",Completed,NA,Phase 2/Phase 3,100,Actual,Nutrin GmbH,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"The trial is meant for pandemic, and any data is fruitful to the society will be shared with researchers only, without compromising personal data of the participant.",2021-02-01T12:08:54Z,2021-02-01T12:08:54Z,63
NCT04492501,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-28,NA,NA,2020-07-28,2020-07-28,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-30,Actual,"April 1, 2020",Actual,2020-04-01,July 2020,2020-07-31,"July 20, 2020",Actual,2020-07-20,"July 20, 2020",Actual,2020-07-20,NA,Interventional,NA,,Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan,"Role of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19",Completed,NA,N/A,600,Actual,UNICEF,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,6 months from completion of study,email,NA,Yes,data can be shared on demand in SPSS sheet,2021-02-01T12:09:08Z,2021-02-01T12:09:08Z,207
NCT04491994,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-28,2020-07-31,NA,2020-08-18,2020-07-28,2020-07-30,Actual,2020-08-18,2020-08-21,Actual,NA,NA,NA,2020-08-18,2020-08-21,Actual,"April 10, 2020",Actual,2020-04-10,August 2020,2020-08-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,COVID-19,sample size calculation was done and 540 patients enrolled,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial,Completed,NA,Phase 3,540,Actual,UNICEF,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,any time when asked,by email,NA,Yes,data can be shared on demand in SPSS sheet,2021-02-01T12:09:12Z,2021-02-01T12:09:12Z,186
NCT04491240,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-27,2020-10-21,NA,2020-10-28,2020-07-27,2020-07-29,Actual,2020-10-28,2020-11-04,Actual,NA,NA,NA,2020-10-28,2020-11-04,Actual,"July 20, 2020",Actual,2020-07-20,October 2020,2020-10-31,"October 20, 2020",Actual,2020-10-20,"October 1, 2020",Actual,2020-10-01,NA,Interventional,COVID-19EXO,,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,The Protocol of Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Two-Sided Pneumonia,Completed,NA,Phase 1/Phase 2,30,Actual,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:09:17Z,2021-02-01T12:09:17Z,115
NCT04487574,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-22,NA,NA,2020-11-11,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Actual,"July 25, 2020",Actual,2020-07-25,November 2020,2020-11-30,"October 29, 2020",Actual,2020-10-29,"October 29, 2020",Actual,2020-10-29,NA,Interventional,NA,,A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19,"A Multicenter, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of XC221, Tablets, 100 mg in Patients With COVID-19",Completed,NA,Phase 3,118,Actual,RSV Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:09:43Z,2021-02-01T12:09:43Z,101
NCT04485169,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-21,NA,NA,2020-09-24,2020-07-22,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-28,Actual,"April 1, 2020",Actual,2020-04-01,September 2020,2020-09-30,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,Plex,,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm; a Retrospective Propensity Matched Control Study,Completed,NA,N/A,280,Actual,UNICEF,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Data is available right now and will remain available (6 months),By email,NA,Yes,data can be shared on demand in SPSS sheet,2021-02-01T12:10:07Z,2021-02-01T12:10:07Z,149
NCT04484493,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-22,NA,NA,2020-11-11,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Actual,"August 8, 2020",Actual,2020-08-08,November 2020,2020-11-30,"November 3, 2020",Actual,2020-11-03,"October 25, 2020",Actual,2020-10-25,NA,Interventional,NA,,Corticosteroid Nasal Spray in COVID-19 Anosmia,Role of Corticosteroid Nasal Spray in Recovery of Smell Sensation in COVID-19 Patients,Completed,NA,Phase 3,100,Actual,Benha University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:10:13Z,2021-02-01T12:10:13Z,101
NCT04483830,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-22,NA,NA,2020-09-07,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2020-09-07,2020-09-09,Actual,"June 5, 2020",Actual,2020-06-05,September 2020,2020-09-30,"September 7, 2020",Actual,2020-09-07,"August 6, 2020",Actual,2020-08-06,NA,Interventional,SulES-COVID,,Suloexide in the Treatment of Early Stages of COVID-19,Sulodexide in the Treatment of Early Stages of COVID-19,Completed,NA,Phase 2/Phase 3,243,Actual,Clinedem,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,individual participant data will be confidential,2021-02-01T12:10:18Z,2021-02-01T12:10:18Z,166
NCT04483375,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-17,NA,NA,2021-01-10,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2021-01-10,2021-01-12,Actual,"July 24, 2020",Actual,2020-07-24,July 2020,2020-07-31,"December 25, 2020",Actual,2020-12-25,"December 25, 2020",Actual,2020-12-25,NA,Interventional,NA,,"Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects","A Randomized, Double-blinded, Placebo-controlled, Single Ascending Dose, Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics of SCTA01 in Healthy Subjects",Completed,NA,Phase 1,33,Actual,Sinocelltech Ltd.,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-02-01T12:10:22Z,2021-02-01T12:10:22Z,41
NCT04479202,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-13,NA,NA,2020-07-19,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-19,2020-07-21,Actual,"February 8, 2020",Actual,2020-02-08,May 2020,2020-05-31,"April 23, 2020",Actual,2020-04-23,"April 18, 2020",Actual,2020-04-18,NA,Interventional,BOIFIM,,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,Completed,NA,Phase 4,76,Actual,Chinese Medical Association,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,We have other articles about covid-19 yet to be published,2021-02-01T12:10:54Z,2021-02-01T12:10:54Z,216
NCT04480593,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-12,NA,NA,2020-09-28,2020-07-20,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-30,Actual,"June 2, 2020",Actual,2020-06-02,September 2020,2020-09-30,"August 30, 2020",Actual,2020-08-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,Bee-Covid,,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,"The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study.",Completed,NA,Phase 2/Phase 3,120,Actual,D'Or Institute for Research and Education,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:10:42Z,2021-02-01T12:10:42Z,145
NCT04479163,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-29,NA,NA,2020-12-19,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-19,2020-12-22,Actual,"June 4, 2020",Actual,2020-06-04,December 2020,2020-12-31,"October 25, 2020",Actual,2020-10-25,"October 25, 2020",Actual,2020-10-25,NA,Interventional,NA,,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2.,Completed,NA,N/A,165,Actual,Fundacion Infant,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:10:55Z,2021-02-01T12:10:55Z,63
NCT04476888,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-16,NA,NA,2021-01-18,2020-07-17,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-01-18,2021-01-20,Actual,"April 26, 2020",Actual,2020-04-26,January 2021,2021-01-31,"October 10, 2020",Actual,2020-10-10,"September 15, 2020",Actual,2020-09-15,NA,Interventional,COLLATE,,Convalescent Plasma Treatment in COVID-19,Convalescent Plasma Treatment in COVID-19 Patients at a Tertiary Care Center in Pakistan,Completed,NA,N/A,110,Actual,Aga Khan University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:11:10Z,2021-02-01T12:11:10Z,33
NCT04475588,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-16,NA,NA,2020-07-16,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"May 1, 2020",Actual,2020-05-01,July 2020,2020-07-31,"July 8, 2020",Actual,2020-07-08,"July 8, 2020",Actual,2020-07-08,NA,Interventional,NA,,Efficacy and Safety of Itolizumab in COVID-19 Complications,"A Multi-Centre, Open Label, Two Arm Randomized, Pivotal Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications",Completed,NA,Phase 2,30,Actual,Biocon Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:11:19Z,2021-02-01T12:11:19Z,219
NCT04475120,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-16,NA,NA,2020-07-16,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"April 15, 2020",Actual,2020-04-15,July 2020,2020-07-31,"July 2, 2020",Actual,2020-07-02,"July 2, 2020",Actual,2020-07-02,NA,Interventional,NA,,Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Interventional Pilot Study to Assess the Use of Oral and Intra-nasal Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Completed,NA,Phase 2/Phase 3,60,Actual,University of Rome Tor Vergata,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2021-02-01T12:11:23Z,2021-02-01T12:11:23Z,219
NCT04473274,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-22,NA,NA,2020-12-02,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-04,Actual,"May 21, 2020",Actual,2020-05-21,December 2020,2020-12-31,"December 1, 2020",Actual,2020-12-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,GOTCHA,,"GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study","GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study",Completed,NA,Phase 4,10,Actual,Samaritan Health Services,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T12:11:36Z,2021-02-01T12:11:36Z,80
NCT04473248,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-14,NA,NA,2020-11-11,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Actual,"June 28, 2020",Actual,2020-06-28,July 2020,2020-07-31,"August 30, 2020",Actual,2020-08-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,,Spartan COVID-19 System: Evaluation of Clinical Sample Collection,Evaluation of Clinical Sample Collection Project: Spartan COVID-19,Completed,NA,N/A,27,Actual,Spartan Bioscience Inc.,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:11:36Z,2021-02-01T12:11:36Z,101
NCT04473170,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-14,NA,NA,2020-07-15,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"April 4, 2020",Actual,2020-04-04,July 2020,2020-07-31,"July 14, 2020",Actual,2020-07-14,"May 20, 2020",Actual,2020-05-20,NA,Interventional,SENTAD-COVID,,Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19,"Adaptive Open-label Study Evaluating the Safety and Efficacy of Autologous Non- Hematopoietic Peripheral Blood Stem Cells Therapy in COVID-19 Outbreak in Abu Dhabi, 2020 (SENTAD-COVID Study)",Completed,NA,Phase 1/Phase 2,146,Actual,Abu Dhabi Stem Cells Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T12:11:36Z,2021-02-01T12:11:36Z,220
NCT04469621,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-28,NA,NA,2020-11-10,2020-07-12,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-13,Actual,"July 17, 2020",Actual,2020-07-17,November 2020,2020-11-30,"October 23, 2020",Actual,2020-10-23,"October 23, 2020",Actual,2020-10-23,NA,Interventional,NA,,A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19,"A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Immunomodulatory Effect of the RIPK1 Inhibitor SAR443122 in Hospitalized Patients With Severe COVID-19",Completed,NA,Phase 1,68,Actual,Sanofi,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-02-01T12:12:07Z,2021-02-01T12:12:07Z,102
NCT04466605,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-09,NA,NA,2020-07-09,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-07-09,2020-07-10,Actual,"March 30, 2020",Actual,2020-03-30,July 2020,2020-07-31,"July 6, 2020",Actual,2020-07-06,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,,Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown,Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown: Randomized Clinical Trial,Completed,NA,N/A,64,Actual,Aarogyam UK,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:12:33Z,2021-02-01T12:12:33Z,226
NCT04460703,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-02,NA,NA,2020-07-18,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-18,2020-07-21,Actual,"July 3, 2020",Actual,2020-07-03,July 2020,2020-07-31,"July 8, 2020",Actual,2020-07-08,"July 8, 2020",Actual,2020-07-08,NA,Interventional,NA,,"COVID-19 Vaccine Messaging, Part 1","Persuasive Messages for COVID-19 Vaccine Uptake: a Randomized Controlled Trial, Part 1",Completed,NA,N/A,4000,Actual,Yale University,,12,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,After publication,Anonymized data and analysis code will be posted in a public replication archive,NA,Yes,Anonymized data and analysis code will be posted in a public replication archive after publication.,2021-02-01T12:13:23Z,2021-02-01T12:13:23Z,217
NCT04460027,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-01,NA,NA,2020-12-15,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-12-15,2020-12-17,Actual,"June 22, 2020",Actual,2020-06-22,December 2020,2020-12-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,,W-SUDs for COVID-19,Woebot for Substance Use Disorders During COVID-19,Completed,NA,Phase 1,180,Actual,"Woebot Labs, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:13:27Z,2021-02-01T12:13:27Z,67
NCT04459520,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-05,NA,NA,2020-08-19,2020-07-05,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-19,2020-08-20,Actual,"July 23, 2020",Actual,2020-07-23,August 2020,2020-08-31,"July 29, 2020",Actual,2020-07-29,"July 28, 2020",Actual,2020-07-28,NA,Interventional,NA,,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,Completed,NA,N/A,1400,Actual,"University of California, Los Angeles",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:13:31Z,2021-02-01T12:13:31Z,185
NCT04459455,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-29,NA,NA,2020-10-19,2020-07-05,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"August 19, 2020",Actual,2020-08-19,October 2020,2020-10-31,"October 15, 2020",Actual,2020-10-15,"October 15, 2020",Actual,2020-10-15,NA,Interventional,NA,,"Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic","Project HF-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic",Completed,NA,N/A,500,Actual,Stony Brook University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:13:32Z,2021-02-01T12:13:32Z,124
NCT04459325,"ClinicalTrials.gov processed this data on January 29, 2021",2020-07-03,NA,NA,2020-10-13,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"June 1, 2020",Actual,2020-06-01,July 2020,2020-07-31,"July 20, 2020",Actual,2020-07-20,"July 20, 2020",Actual,2020-07-20,NA,Interventional,NA,,TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,A Prospective Open-label Study of the TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,Completed,NA,Phase 3,100,Actual,AO GENERIUM,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:13:32Z,2021-02-01T12:13:32Z,130
NCT04458363,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-25,NA,NA,2021-01-14,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-14,2021-01-19,Actual,"July 4, 2020",Actual,2020-07-04,January 2021,2021-01-31,"September 1, 2020",Actual,2020-09-01,"September 1, 2020",Actual,2020-09-01,NA,Interventional,NA,,Convalescent Plasma in Pediatric COVID-19,Convalescent Plasma to Optimize Treatment of COVID-19 Disease in Pediatric Patients: A Feasibility Study,Completed,NA,Early Phase 1,3,Actual,Emory University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:13:40Z,2021-02-01T12:13:40Z,37
NCT04457388,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-30,NA,NA,2020-07-07,2020-06-30,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-08,Actual,"March 25, 2020",Actual,2020-03-25,July 2020,2020-07-31,"June 15, 2020",Actual,2020-06-15,"June 15, 2020",Actual,2020-06-15,NA,Interventional,NA,,Tele-Yoga Therapy for Chronic Pain,Tele- Yoga Therapy for Patients With Chronic Pain During Covid-19 Lockdown: A Prospective Non-randomized Single Arm Clinical Trial,Completed,NA,N/A,18,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:13:47Z,2021-02-01T12:13:47Z,228
NCT04456452,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-30,NA,NA,2021-01-12,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-12,2021-01-13,Actual,"July 27, 2020",Actual,2020-07-27,January 2021,2021-01-31,"November 30, 2020",Actual,2020-11-30,"September 8, 2020",Actual,2020-09-08,NA,Interventional,NA,,Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation,A Randomized Controlled Trial to Evaluate the Safety of Intravenous Ampionâ„¢ in Adult COVID-19 Patients Requiring Oxygen Supplementation,Completed,NA,Phase 1,10,Actual,Ampio Pharmaceuticals. Inc.,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:14:00Z,2021-02-01T12:14:00Z,39
NCT04454606,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-26,NA,NA,2020-06-30,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"May 31, 2020",Actual,2020-05-31,"May 15, 2020",Actual,2020-05-15,NA,Interventional,NA,,The New Silicone N99 Half-Piece Respirator,The New Silicone N99 Half-Piece Respirator:VJR-NMU N99:New and Effective Tool to Prevent COVID-19,Completed,NA,N/A,43,Actual,Bangkok Metropolitan Administration Medical College and Vajira Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:14:12Z,2021-02-01T12:14:12Z,235
NCT04455308,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-30,NA,NA,2020-11-03,2020-07-01,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"July 21, 2020",Actual,2020-07-21,November 2020,2020-11-30,"October 19, 2020",Actual,2020-10-19,"October 19, 2020",Actual,2020-10-19,NA,Interventional,ECCES,,COVID-19 and Chilblains,"Chilblains, COVID-19 and Lockdown: Epidemiologic Study",Completed,NA,N/A,269,Actual,Rennes University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:14:08Z,2021-02-01T12:14:08Z,109
NCT04452435,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-29,NA,NA,2020-10-19,2020-06-29,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"July 21, 2020",Actual,2020-07-21,October 2020,2020-10-31,"October 13, 2020",Actual,2020-10-13,"October 13, 2020",Actual,2020-10-13,NA,Interventional,NA,,Safety and Efficacy of C21 in Subjects With COVID-19,"A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial Investigating the Safety and Efficacy of C21 in Hospitalised Subjects With COVID-19 Infection Not Requiring Mechanical Ventilation",Completed,NA,Phase 2,106,Actual,Vicore Pharma AB,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:14:29Z,2021-02-01T12:14:29Z,124
NCT04449718,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-16,NA,NA,2020-11-16,2020-06-25,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-16,2020-11-17,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,"October 7, 2020",Actual,2020-10-07,"October 7, 2020",Actual,2020-10-07,NA,Interventional,NA,,Vitamin D Supplementation in Patients With COVID-19,"Vitamin D Supplementation in Patients With COVID-19: A Randomized, Double-blind, Placebo-controlled Trial",Completed,NA,N/A,240,Actual,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T12:14:50Z,2021-02-01T12:14:50Z,96
NCT04448769,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-23,NA,NA,2020-08-18,2020-06-25,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"June 26, 2020",Actual,2020-06-26,August 2020,2020-08-31,"July 24, 2020",Actual,2020-07-24,"July 24, 2020",Actual,2020-07-24,NA,Interventional,COVAL-NANCY,,Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19),Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19) in the Population of the Grand Nancy Metropolitan Area,Completed,NA,N/A,2006,Actual,"Central Hospital, Nancy, France",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-02-01T12:14:59Z,2021-02-01T12:14:59Z,186
NCT04446104,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-11,NA,NA,2020-10-13,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-19,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,NA,Interventional,NA,,A Preventive Treatment for Migrant Workers at High-risk of COVID-19,A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial),Completed,NA,Phase 3,4257,Actual,"National University Hospital, Singapore",,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:15:19Z,2021-02-01T12:15:19Z,130
NCT04445376,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-22,NA,NA,2020-10-06,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"July 3, 2020",Actual,2020-07-03,October 2020,2020-10-31,"October 3, 2020",Actual,2020-10-03,"September 10, 2020",Actual,2020-09-10,NA,Interventional,NA,,Effect of Physical Therapy Exercises on Cardiorespiratory Fitness Level in COVID19 Patients After Recovery.,Effect of Aerobic Exercises on Cardio-respiratory Fitness and Quality of Life in Recovered COVID 19 Recovered Patients.,Completed,NA,N/A,20,Actual,Government College University Faisalabad,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:15:25Z,2021-02-01T12:15:25Z,137
NCT04442958,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-17,NA,NA,2020-06-30,2020-06-19,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"May 15, 2020",Actual,2020-05-15,June 2020,2020-06-30,"June 17, 2020",Actual,2020-06-17,"June 15, 2020",Actual,2020-06-15,NA,Interventional,NA,,Effectiveness of Convalescent Immune Plasma Therapy,Effectiveness of Convalescent Immune Plasma Therapy in Severe COVID-19 Patients With Acute Respiratory Distress Syndrome,Completed,NA,N/A,60,Actual,Bagcilar Training and Research Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-02-01T12:15:44Z,2021-02-01T12:15:44Z,235
NCT04441632,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-18,NA,NA,2020-08-11,2020-06-18,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"June 15, 2020",Actual,2020-06-15,August 2020,2020-08-31,"July 30, 2020",Actual,2020-07-30,"July 26, 2020",Actual,2020-07-26,NA,Interventional,TEAM-ICU,,Effect of Positive Attitudes on Behavior and Wellness,"The Impact of Positive Reinforcement on Teamwork Climate, Resiliency, and Burnout During the COVID-19 Pandemic: the TEAM-ICU Study (Transforming Employee Attitudes Via Messaging Strengthens Interconnection, Communication, and Unity)",Completed,NA,N/A,24,Actual,Cedars-Sinai Medical Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:15:58Z,2021-02-01T12:15:58Z,193
NCT04441424,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-12,NA,NA,2020-06-20,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-20,2020-06-23,Actual,"April 3, 2020",Actual,2020-04-03,June 2020,2020-06-30,"June 1, 2020",Actual,2020-06-01,"June 1, 2020",Actual,2020-06-01,NA,Interventional,NA,,Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,"The Therapeutic Potential of Convalescent Plasma Therapy on Treating Critically-ill COVID-19 Patients Residing in Respiratory Care Units in Hospitals in Baghdad, Iraq",Completed,NA,N/A,49,Actual,Alkarkh Health Directorate-Baghdad,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:15:59Z,2021-02-01T12:15:59Z,245
NCT04437875,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-16,NA,NA,2020-08-11,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"June 17, 2020",Actual,2020-06-17,June 2020,2020-06-30,"August 10, 2020",Actual,2020-08-10,"August 3, 2020",Actual,2020-08-03,NA,Interventional,NA,,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac Lyo"" Lyophilizate for the Preparation of a Solution for Intramuscular Injection With the Participation of Healthy Volunteers",Completed,NA,Phase 1/Phase 2,38,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:16:24Z,2021-02-01T12:16:24Z,193
NCT04436471,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-16,NA,NA,2020-08-11,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"June 17, 2020",Actual,2020-06-17,June 2020,2020-06-30,"August 10, 2020",Actual,2020-08-10,"August 3, 2020",Actual,2020-08-03,NA,Interventional,NA,,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" a Solution for Intramuscular Injection With the Participation of Healthy Volunteers",Completed,NA,Phase 1/Phase 2,38,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:16:34Z,2021-02-01T12:16:34Z,193
NCT04435184,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-16,NA,NA,2021-01-14,2020-06-16,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2021-01-14,2021-01-19,Actual,"July 9, 2020",Actual,2020-07-09,January 2021,2021-01-31,"January 4, 2021",Actual,2021-01-04,"November 28, 2020",Actual,2020-11-28,NA,Interventional,CRITICAL,,Crizanlizumab for Treating COVID-19 Vasculopathy,Crizanlizumab for Treating COVID-19 Vasculopathy,Completed,NA,Phase 2,50,Actual,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:16:45Z,2021-02-01T12:16:45Z,37
NCT04431856,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-12,NA,NA,2020-11-30,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-30,2020-12-01,Actual,"May 15, 2020",Actual,2020-05-15,November 2020,2020-11-30,"November 17, 2020",Actual,2020-11-17,"November 17, 2020",Actual,2020-11-17,NA,Interventional,Co-PARENT,,CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment,CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment,Completed,NA,N/A,80,Actual,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:17:19Z,2021-02-01T12:17:19Z,82
NCT04426318,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-09,NA,NA,2021-01-22,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-22,2021-01-26,Actual,"June 14, 2020",Actual,2020-06-14,November 2020,2020-11-30,"January 12, 2021",Actual,2021-01-12,"January 12, 2021",Actual,2021-01-12,NA,Interventional,CAHMP-ED,,COVID-19 and the Healthy Minds Program for Educators,COVID-19 and the Healthy Minds Program for Educators,Completed,NA,N/A,733,Actual,"University of Wisconsin, Madison",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Data will be de-identified and made publicly available based on the publication of preregistered study hypotheses following peer review.,Researcher consent. Any reasonable request will be granted.,NA,Yes,"Data will be de-identified and listed in public data registries (i.e., osf) based on the publication of preregistered study hypotheses on a manuscript by manuscript basis.",2021-02-01T12:18:04Z,2021-02-01T12:18:04Z,29
NCT04425252,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-09,NA,NA,2021-01-15,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-15,2021-01-19,Actual,"August 1, 2020",Actual,2020-08-01,January 2021,2021-01-31,"December 29, 2020",Actual,2020-12-29,"December 29, 2020",Actual,2020-12-29,NA,Interventional,CRISIS,,Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19,The CRISIS Study: A Randomized Open-label Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Hospitalized Adults With Coronavirus-19 (COVID-19),Completed,NA,Phase 1/Phase 2,23,Actual,"Clear Creek Bio, Inc.",,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:18:12Z,2021-02-01T12:18:12Z,36
NCT04425005,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-08,NA,NA,2021-01-18,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-18,2021-01-22,Actual,"May 10, 2020",Actual,2020-05-10,January 2021,2021-01-31,"December 7, 2020",Actual,2020-12-07,"December 7, 2020",Actual,2020-12-07,NA,Interventional,NA,,Home-based Exercise Training During Covid-19 Pandemic in Post-bariatric,Effect of Home-based Exercise Training Program During the Covid-19 Pandemic in Post-bariatric Patients: A Randomized Controlled Trial,Completed,NA,N/A,55,Actual,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:18:14Z,2021-02-01T12:18:14Z,33
NCT04423991,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-08,NA,NA,2020-06-08,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-09,Actual,"March 10, 2020",Actual,2020-03-10,June 2020,2020-06-30,"June 4, 2020",Actual,2020-06-04,"June 4, 2020",Actual,2020-06-04,NA,Interventional,IDENTIFY,,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning: the IDENTIFY Trial,Completed,NA,N/A,290,Actual,Dascena,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:18:22Z,2021-02-01T12:18:22Z,257
NCT04423289,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-06,NA,NA,2020-06-08,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-09,Actual,"March 31, 2020",Actual,2020-03-31,June 2020,2020-06-30,"May 18, 2020",Actual,2020-05-18,"May 4, 2020",Actual,2020-05-04,NA,Interventional,NA,,Telematic Monitoring Through a Mobile Application of Patients With COVID-19,COVID Follow-App: Telematic Monitoring Through a Mobile Application of Patients With COVID-19: A Randomized Clinical Trial,Completed,NA,N/A,150,Actual,Hospital Universitari Vall d'Hebron Research Institute,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:18:27Z,2021-02-01T12:18:27Z,257
NCT04422561,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-06,2020-08-23,NA,2020-08-23,2020-06-06,2020-06-09,Actual,2020-08-23,2020-08-27,Actual,NA,NA,NA,2020-08-23,2020-08-27,Actual,"May 31, 2020",Actual,2020-05-31,August 2020,2020-08-31,"July 27, 2020",Actual,2020-07-27,"July 14, 2020",Actual,2020-07-14,NA,Interventional,NA,,Prophylactic Ivermectin in COVID-19 Contacts,Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19,Completed,NA,Phase 2/Phase 3,340,Actual,Zagazig University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:18:31Z,2021-02-01T12:18:31Z,181
NCT04420806,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-05,NA,NA,2020-11-12,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Actual,"March 14, 2020",Actual,2020-03-14,November 2020,2020-11-30,"October 30, 2020",Actual,2020-10-30,"July 30, 2020",Actual,2020-07-30,NA,Interventional,NA,,Effects of COVID-19 Lockdown in Exercising Early Postmenopausal Women,Effects of Three Months of COVID-19 Lockdown Induced Deconditioning After 13 Months of High Intensity Exercise Training in Early Postmenopausal Women,Completed,NA,N/A,21,Actual,University of Erlangen-NÃ¼rnberg Medical School,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:18:43Z,2021-02-01T12:18:43Z,100
NCT04420247,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-02,NA,NA,2020-10-23,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-27,Actual,"April 16, 2020",Actual,2020-04-16,October 2020,2020-10-31,"September 3, 2020",Actual,2020-09-03,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,,Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Multicentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Completed,NA,Phase 3,142,Actual,Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-02-01T12:18:48Z,2021-02-01T12:18:48Z,120
NCT04418947,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-29,NA,NA,2020-07-29,2020-06-02,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-31,Actual,"June 15, 2020",Actual,2020-06-15,July 2020,2020-07-31,"July 17, 2020",Actual,2020-07-17,"July 17, 2020",Actual,2020-07-17,NA,Interventional,NA,,Project Resurgence Communication Trial,Comparison of the Effectiveness of Communication Strategies on the Return to In-Person Visits to a Medical Center After the Emergence of COVID-19: A Randomized Trial,Completed,NA,N/A,11120,Actual,University of Pennsylvania,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:18:58Z,2021-02-01T12:18:58Z,206
NCT04413968,"ClinicalTrials.gov processed this data on January 29, 2021",2020-06-02,NA,NA,2020-10-23,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"June 2, 2020",Actual,2020-06-02,May 2020,2020-05-31,"October 2, 2020",Actual,2020-10-02,"July 2, 2020",Actual,2020-07-02,NA,Interventional,COVIDOCRECHE,,"COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants","Contamination and Transmission of the SARS-CoV-2 Virus in Exposed, Confined and Community-based Infants: A Cross-sectional, Multicentre, Interventional Seroprevalence Study",Completed,NA,N/A,600,Actual,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:19:34Z,2021-02-01T12:19:34Z,120
NCT04412343,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-29,NA,NA,2020-11-02,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"May 23, 2020",Actual,2020-05-23,November 2020,2020-11-30,"October 5, 2020",Actual,2020-10-05,"October 5, 2020",Actual,2020-10-05,NA,Interventional,SCOPE,,The Seniors COvid-19 Pandemic and Exercise Study,The Seniors COvid-19 Pandemic and Exercise Study: A Randomized Controlled Trial,Completed,NA,N/A,241,Actual,University of British Columbia,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Data will be available from this trial 1 year after completion of the study. The data will remain available indefinitely.,"The nature of the request for sharing access will be reviewed by the PI (Beauchamp, M) and the data management team. Data will be shared via secure platforms (Redcap). Contact for data access can be done through personal communications (e.g., email) with PI Beauchamp.",https://osf.io/xw9gm,Yes,"The protocol for this study will be available on Open Science Framework (after 4 months to allow for study completion). The Statistical Analysis Plan will also be available on Open Science Framework. The Consent form is freely available if requested from the Primary Investigator (PI: Beauchamp, M.).",2021-02-01T12:19:45Z,2021-02-01T12:19:45Z,110
NCT04411628,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-29,NA,NA,2020-10-29,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"May 28, 2020",Actual,2020-05-28,October 2020,2020-10-31,"August 26, 2020",Actual,2020-08-26,"August 26, 2020",Actual,2020-08-26,NA,Interventional,NA,,A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19,"A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19",Completed,NA,Phase 1,24,Actual,Eli Lilly and Company,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-02-01T12:19:51Z,2021-02-01T12:19:51Z,114
NCT04410692,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-27,NA,NA,2020-05-30,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-30,2020-06-02,Actual,"May 15, 2020",Actual,2020-05-15,May 2020,2020-05-31,"May 17, 2020",Actual,2020-05-17,"May 16, 2020",Actual,2020-05-16,NA,Interventional,NA,,Can the Prediction Market Improve Predictions of COVID-19?,Can the Prediction Market Improve Predictions of COVID-19?,Completed,NA,N/A,560,Actual,"National University, Singapore",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,After completion of all analysis. It will be made available in the supporting documentation.,It will be made available in the supporting documentation.,NA,Yes,"Investigators will not be storing or sharing any personal identifiers. All individual level data will be anonymized, and only anonymized data will be shared with other researchers, upon request.",2021-02-01T12:19:59Z,2021-02-01T12:19:59Z,266
NCT04410159,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-27,2020-07-08,NA,2020-07-17,2020-05-28,2020-06-01,Actual,2020-07-17,2020-07-21,Actual,NA,NA,NA,2020-07-17,2020-07-21,Actual,"June 22, 2020",Actual,2020-06-22,July 2020,2020-07-31,"July 6, 2020",Actual,2020-07-06,"June 29, 2020",Actual,2020-06-29,NA,Interventional,GARGLES,,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,"A Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 Patients",Completed,NA,Phase 2,20,Actual,Universiti Sains Islam Malaysia,Inadequate budget for laboratory test lead to small numbers of subjects analyzed,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,September to December 2020,email to drnurul@usim.edu.my,NA,Yes,The participant data from the final research dataset used in the published manuscript will be shared upon reasonable request. The protocol and data analysis will be shared in clinicaltrial,2021-02-01T12:20:04Z,2021-02-01T12:20:04Z,218
NCT04409509,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-28,NA,NA,2021-01-21,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-22,Actual,"July 1, 2020",Actual,2020-07-01,January 2021,2021-01-31,"January 12, 2021",Actual,2021-01-12,"January 12, 2021",Actual,2021-01-12,NA,Interventional,NA,,Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19),"A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)",Completed,NA,Phase 2,124,Actual,CSL Behring,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.,"Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.
An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.
The requesting party must execute an appropriate data sharing agreement before IPD will be made available.",NA,Yes,"CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.
Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.
If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.",2021-02-01T12:20:09Z,2021-02-01T12:20:09Z,30
NCT04408456,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-24,NA,NA,2020-08-01,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-08-01,2020-08-04,Actual,"March 1, 2020",Actual,2020-03-01,August 2020,2020-08-31,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,PEP-CQ,,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 in Asymptomatic Individual at Risk for SARS-CoV-2 Infection-A Open Level Control Clinical Trial,Completed,NA,Phase 3,325,Actual,Postgraduate Institute of Medical Education and Research,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Data will be shared with the concerned authority and Institutional Ethics committee as and when required.,2021-02-01T12:20:17Z,2021-02-01T12:20:17Z,203
NCT04407208,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-16,NA,NA,2020-06-27,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-27,2020-06-30,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"June 22, 2020",Actual,2020-06-22,"June 22, 2020",Actual,2020-06-22,NA,Interventional,NA,,Convalescent Plasma Therapy in Patients With COVID-19,Convalescent Plasma Therapy in Patients With COVID-19,Completed,NA,Phase 1,10,Actual,Biofarma,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T12:20:26Z,2021-02-01T12:20:26Z,238
NCT04407182,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-25,NA,NA,2021-01-07,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-08,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,"October 1, 2020",Actual,2020-10-01,"August 1, 2020",Actual,2020-08-01,NA,Interventional,NA,,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients in Teodoro Maldonado Carbo Specialty's Hospital Infected and Diagnosed by SARS-Cov-2 With COVID-19,Completed,NA,Phase 2,60,Actual,Catalysis SL,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-02-01T12:20:26Z,2021-02-01T12:20:26Z,44
NCT04407286,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-19,NA,NA,2020-11-30,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-30,2020-12-02,Actual,"May 19, 2020",Actual,2020-05-19,November 2020,2020-11-30,"November 30, 2020",Actual,2020-11-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,,Vitamin D Testing and Treatment for COVID 19,Vitamin D Testing and Treatment for Adults With COVID 19,Completed,NA,Phase 1,41,Actual,Arizona State University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,Contact us if you wish to discuss sharing of de-identified data,2021-02-01T12:20:26Z,2021-02-01T12:20:26Z,82
NCT04405843,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-23,NA,NA,2020-12-24,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-12-24,2020-12-28,Actual,"July 14, 2020",Actual,2020-07-14,December 2020,2020-12-31,"December 21, 2020",Actual,2020-12-21,"December 21, 2020",Actual,2020-12-21,NA,Interventional,EPIC,,Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial),"Randomized, Placebo Controlled, Double Blind Clinical Trial to Evaluate the Efficacy of Molecule D11AX22 in Adults Patients From Valle Del Cauca, Colombia With Early Stages of SARS COV2 / COVID-19",Completed,NA,Phase 2/Phase 3,476,Actual,Centro de Estudios en InfectogÃ­a Pediatrica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-02-01T12:20:36Z,2021-02-01T12:20:36Z,58
NCT04405999,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-18,NA,NA,2020-09-02,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-09-02,2020-09-03,Actual,"May 14, 2020",Actual,2020-05-14,September 2020,2020-09-30,"August 31, 2020",Actual,2020-08-31,"August 9, 2020",Actual,2020-08-09,NA,Interventional,NA,,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial,Completed,NA,Phase 4,50,Actual,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:20:34Z,2021-02-01T12:20:34Z,171
NCT04405544,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-26,NA,NA,2020-10-29,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"May 22, 2020",Actual,2020-05-22,October 2020,2020-10-31,"October 29, 2020",Actual,2020-10-29,"July 22, 2020",Actual,2020-07-22,NA,Interventional,NA,,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Completed,NA,N/A,51,Actual,"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:20:37Z,2021-02-01T12:20:37Z,114
NCT04405310,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-26,NA,NA,2020-12-16,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-12-16,2020-12-21,Actual,"May 20, 2020",Actual,2020-05-20,December 2020,2020-12-31,"December 10, 2020",Actual,2020-12-10,"November 20, 2020",Actual,2020-11-20,NA,Interventional,CPC-SARS,,Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,"Plasma From Covalescent Donors With Covid-19 for the Management of Patients With SARS-COV-2 Fase II and III, a Doble Center Randomized Doble Blind Trial",Completed,NA,Phase 2,42,Actual,Grupo Mexicano para el Estudio de la Medicina Intensiva,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,3 months after completion up to five years,"proposal should be directed to gmemiinv@gmails.com, to gain access, requestor will need to sign a data access agreement",NA,Yes,IPD will be shared by petition.,2021-02-01T12:20:39Z,2021-02-01T12:20:39Z,66
NCT04402983,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-22,NA,NA,2020-12-11,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-14,Actual,"May 27, 2020",Actual,2020-05-27,May 2020,2020-05-31,"December 1, 2020",Actual,2020-12-01,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,Completed,NA,N/A,34,Actual,Istanbul Medipol University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:21:03Z,2021-02-01T12:21:03Z,71
NCT04401579,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-22,NA,NA,2020-11-30,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-11-30,2020-12-02,Actual,"May 8, 2020",Actual,2020-05-08,April 2020,2020-04-30,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-2)",Completed,NA,Phase 3,1034,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-02-01T12:21:17Z,2021-02-01T12:21:17Z,82
NCT04400279,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-21,NA,NA,2021-01-08,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"June 1, 2020",Actual,2020-06-01,January 2021,2021-01-31,"November 28, 2020",Actual,2020-11-28,"November 28, 2020",Actual,2020-11-28,NA,Interventional,COPE,,The COVID-19 Pandemic and Exercise Study,COvid-19 Pandemic and Exercise (COPE) Trial: A Randomized Study Examining Physical Activities and Wellbeing in Individuals Mandated to Stay at Home,Completed,NA,N/A,334,Actual,University of British Columbia,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"4 months following trial's end, materials will be made available. following publication, all data will be made available.",Investigators whose proposed use of the data has been approved by an independent review committee identified for the purpose for the purpose of meta-analyses and to achieve aims in the approved proposal. Investigators of the study need to approve the proposals. Proposals should be directed to eli.puterman@Ubc.ca,https://osf.io/g9xqp,Yes,"All of the individual participant data collected during the trial, after de-identification upon request and cleared for approval by principal investigator.
All of the protocols, statistical analysis plan, informed consent form, analytic code.",2021-02-01T12:21:27Z,2021-02-01T12:21:27Z,43
NCT04399005,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-19,NA,NA,2020-06-23,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-25,Actual,"May 25, 2020",Actual,2020-05-25,May 2020,2020-05-31,"June 10, 2020",Actual,2020-06-10,"June 5, 2020",Actual,2020-06-05,NA,Interventional,NA,,The Efficacy Comparing Daily and After-each-case Room Disinfection.,The Efficacy Comparing Daily and After-each-case Room Disinfection in the Endoscopy Unit During the COVID-19 Pandemic.,Completed,NA,N/A,240,Actual,The First Affiliated Hospital of Zhejiang Chinese Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,individual participant data sharing will be consider after study,2021-02-01T12:21:36Z,2021-02-01T12:21:36Z,242
NCT04398004,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-17,NA,NA,2021-01-08,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"May 6, 2020",Actual,2020-05-06,January 2021,2021-01-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,ACHIEVE,,Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,Anti-inflammatory Clarithromycin to Improve SARS-CoV-2 (COVID-19) Infection Early: The ACHIEVE Open-label Non-randomized Clinical Trial,Completed,NA,Phase 2,90,Actual,Hellenic Institute for the Study of Sepsis,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:21:44Z,2021-02-01T12:21:44Z,43
NCT04397562,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-19,NA,NA,2020-11-17,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-11-17,2020-11-18,Actual,"April 29, 2020",Actual,2020-04-29,November 2020,2020-11-30,"August 3, 2020",Actual,2020-08-03,"July 3, 2020",Actual,2020-07-03,NA,Interventional,CORONA,,A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptively Designed Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19",Completed,NA,Phase 3,206,Actual,Biocad,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:21:47Z,2021-02-01T12:21:47Z,95
NCT04393818,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-18,NA,NA,2020-09-09,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-09,2020-09-10,Actual,"May 5, 2020",Actual,2020-05-05,August 2020,2020-08-31,"August 24, 2020",Actual,2020-08-24,"August 24, 2020",Actual,2020-08-24,NA,Interventional,PsyCovid_App,,Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19,A Double-blinded Randomized Controlled Trial to Examine the Effectiveness of a Mobile-based Intervention to Reduce Mental Health Problems in Healthcare Workers at the Frontline Against COVID-19 in Spain: the PsyCovidApp Trial,Completed,NA,Phase 3,560,Actual,FundaciÃ³ d'investigaciÃ³ SanitÃ ria de les Illes Balears,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:22:19Z,2021-02-01T12:22:19Z,164
NCT04393077,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-11,NA,NA,2020-11-20,2020-05-15,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-11-20,2020-11-24,Actual,"May 10, 2020",Actual,2020-05-10,November 2020,2020-11-30,"May 20, 2020",Actual,2020-05-20,"May 15, 2020",Actual,2020-05-15,NA,Interventional,NA,,Emotional Freedom Technique (EFT) Effect on Nurses,"Emotional Freedom Technique (EFT) Effect on Nurses' Stress, Anxiety and Burnout Levels During the COVID-19 Pandemic Process: A Randomized Controlled Study",Completed,NA,N/A,80,Actual,Istanbul Saglik Bilimleri University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:22:27Z,2021-02-01T12:22:27Z,92
NCT04392414,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-13,NA,NA,2020-09-23,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"September 23, 2020",Actual,2020-09-23,"July 10, 2020",Actual,2020-07-10,NA,Interventional,NA,,Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,"Randomized, Open Label, Prospective Study of the Safety and Efficacy of Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease",Completed,NA,Phase 2,60,Actual,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,There is no current plan to share individual participant data (IPD).,2021-02-01T12:22:33Z,2021-02-01T12:22:33Z,150
NCT04392219,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-29,NA,NA,2020-08-14,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-17,Actual,"April 10, 2020",Actual,2020-04-10,August 2020,2020-08-31,"August 11, 2020",Actual,2020-08-11,"August 11, 2020",Actual,2020-08-11,NA,Interventional,NA,,"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers","A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of EIDD-2801 Following Oral Administration to Healthy Volunteers",Completed,NA,Phase 1,130,Actual,"Ridgeback Biotherapeutics, LP",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:22:35Z,2021-02-01T12:22:35Z,190
NCT04391712,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-04,NA,NA,2020-08-03,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-05,Actual,"April 30, 2020",Actual,2020-04-30,August 2020,2020-08-31,"July 16, 2020",Actual,2020-07-16,"May 15, 2020",Actual,2020-05-15,NA,Interventional,NA,,Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Multiwave Locked System (MLS) Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Completed,NA,Phase 2,10,Actual,Lowell General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2021-02-01T12:22:49Z,2021-02-01T12:22:49Z,201
NCT04391127,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-12,NA,NA,2020-11-06,2020-05-14,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"May 4, 2020",Actual,2020-05-04,November 2020,2020-11-30,"November 6, 2020",Actual,2020-11-06,"November 6, 2020",Actual,2020-11-06,NA,Interventional,NA,,Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial,Completed,NA,Phase 3,108,Actual,Centenario Hospital Miguel Hidalgo,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:23:07Z,2021-02-01T12:23:07Z,106
NCT04390516,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-14,NA,NA,2020-06-10,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-12,Actual,"March 24, 2020",Actual,2020-03-24,June 2020,2020-06-30,"May 30, 2020",Actual,2020-05-30,"May 4, 2020",Actual,2020-05-04,NA,Interventional,READY,,Respiratory Decompensation and Model for the Triage of COVID-19 Patients,Prediction Of Respiratory Decompensation In Covid-19 Patients Using Machine Learning: The READY Trial,Completed,NA,N/A,197,Actual,Dascena,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:23:28Z,2021-02-01T12:23:28Z,255
NCT04390022,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-07,2020-12-09,NA,2020-12-10,2020-05-14,2020-05-15,Actual,2020-12-10,2020-12-17,Actual,NA,NA,NA,2020-12-10,2020-12-17,Actual,"July 31, 2020",Actual,2020-07-31,December 2020,2020-12-31,"October 9, 2020",Actual,2020-10-09,"September 17, 2020",Actual,2020-09-17,NA,Interventional,SAINT,,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission,Completed,NA,Phase 2,24,Actual,"Clinica Universidad de Navarra, Universidad de Navarra",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:23:43Z,2021-02-01T12:23:43Z,72
NCT04389944,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-12,NA,NA,2020-08-03,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-04,Actual,"March 31, 2020",Actual,2020-03-31,August 2020,2020-08-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe Coronavirus Disease 2019 Infectious Disease (COVID-19),Completed,NA,N/A,15,Actual,"University Hospital, Basel, Switzerland",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:23:43Z,2021-02-01T12:23:43Z,201
NCT04389333,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-09,NA,NA,2020-07-19,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-07-19,2020-07-21,Actual,"March 26, 2020",Actual,2020-03-26,July 2020,2020-07-31,"May 20, 2020",Actual,2020-05-20,"April 26, 2020",Actual,2020-04-26,NA,Interventional,NA,,Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic,"Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic: a Prospective, Open-label, Pilot, Randomized Trial",Completed,NA,N/A,40,Actual,Changhai Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:23:47Z,2021-02-01T12:23:47Z,216
NCT04386694,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-08,NA,NA,2020-10-28,2020-05-11,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-29,Actual,"May 18, 2020",Actual,2020-05-18,October 2020,2020-10-31,"September 17, 2020",Actual,2020-09-17,"September 17, 2020",Actual,2020-09-17,NA,Interventional,NA,,Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19,Is Photobiomodulation Therapy (PBMT) Combined With Static Magnetic Field (sMF) Able to Decrease the Intensive Care Unit (ICU) Length of Stay for Patients With COVID-19?,Completed,NA,N/A,30,Actual,University of Nove de Julho,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2021-02-01T12:24:17Z,2021-02-01T12:24:17Z,115
NCT04385810,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-29,NA,NA,2020-11-13,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-11-13,2020-11-16,Actual,"April 27, 2020",Actual,2020-04-27,November 2020,2020-11-30,"July 29, 2020",Actual,2020-07-29,"July 29, 2020",Actual,2020-07-29,NA,Interventional,DOCOV,,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Completed,NA,N/A,23,Actual,Fondation Ophtalmologique Adolphe de Rothschild,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:24:25Z,2021-02-01T12:24:25Z,99
NCT04384380,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-07,NA,NA,2020-07-31,2020-05-10,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-07-31,2020-08-04,Actual,"April 1, 2020",Actual,2020-04-01,March 2020,2020-03-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,"A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment",Completed,NA,N/A,33,Actual,Taoyuan General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,The study outcome will be shared with the experts and persons interested in this field.,2021-02-01T12:24:38Z,2021-02-01T12:24:38Z,204
NCT04382560,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-05,NA,NA,2020-09-24,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-25,Actual,"May 2, 2020",Actual,2020-05-02,September 2020,2020-09-30,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,Coping Strategies and Responsiveness to a Brief Online Intervention During COVID-19 Pandemic,Resting Heart Rate Variability as a Predictor of Coping Strategies and Responsiveness to a Brief Online Intervention During Forced Quarantine,Completed,NA,N/A,69,Actual,University of Parma,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:24:53Z,2021-02-01T12:24:53Z,149
NCT04729491,"ClinicalTrials.gov processed this data on January 29, 2021",2021-01-25,NA,NA,2021-01-25,2021-01-25,2021-01-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-28,Actual,"June 30, 2020",Actual,2020-06-30,June 2020,2020-06-30,"October 7, 2020",Actual,2020-10-07,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,,EAT-DUTA AndroCoV Trial,Early Antiandrogen Treatment (EAT) With Dutasteride for COVID-19 (EAT-DUTA AndroCoV Trial),Completed,NA,Phase 2/Phase 3,138,Actual,Corpometria Institute,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:25:19Z,2021-02-01T12:25:19Z,26
NCT04380519,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-06,NA,NA,2020-09-28,2020-05-06,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"April 23, 2020",Actual,2020-04-23,September 2020,2020-09-30,"July 24, 2020",Actual,2020-07-24,"July 10, 2020",Actual,2020-07-10,NA,Interventional,NA,,Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),"An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)",Completed,NA,Phase 2/Phase 3,372,Actual,R-Pharm,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:25:17Z,2021-02-01T12:25:17Z,145
NCT04379661,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-05,NA,NA,2021-01-07,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-08,Actual,"May 7, 2020",Actual,2020-05-07,January 2021,2021-01-31,"August 31, 2020",Actual,2020-08-31,"July 7, 2020",Actual,2020-07-07,NA,Interventional,NA,,SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,SUNLIGHT Study: Online Support Groups for Multiple Sclerosis (MS) to Address COVID-19,Completed,NA,N/A,32,Actual,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:25:24Z,2021-02-01T12:25:24Z,44
NCT04378712,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-29,NA,NA,2020-05-13,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"January 21, 2020",Actual,2020-01-21,May 2020,2020-05-31,"March 23, 2020",Actual,2020-03-23,"March 23, 2020",Actual,2020-03-23,NA,Interventional,NA,,Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),"Effects of Hydrogen/Oxygen Mixed Gas Inhalation for Patients With Coronavirus Disease 2019 (COVID-19) Who Had Dyspnea: A Multicenter, Open-label Clinical Trial",Completed,NA,N/A,90,Actual,Guangzhou Institute of Respiratory Disease,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:25:32Z,2021-02-01T12:25:32Z,283
NCT04375098,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-03,NA,NA,2020-09-12,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-12,2020-09-16,Actual,"May 4, 2020",Actual,2020-05-04,September 2020,2020-09-30,"August 17, 2020",Actual,2020-08-17,"August 17, 2020",Actual,2020-08-17,NA,Interventional,NA,,Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection,Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection: a Randomized Phase II Trial,Completed,NA,Phase 2,58,Actual,Pontificia Universidad Catolica de Chile,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:26:09Z,2021-02-01T12:26:09Z,161
NCT04374032,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-30,NA,NA,2020-12-23,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-24,Actual,"May 1, 2020",Actual,2020-05-01,December 2020,2020-12-31,"November 3, 2020",Actual,2020-11-03,"October 7, 2020",Actual,2020-10-07,NA,Interventional,NA,,Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection,"An Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTENÂ® as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 Infection",Completed,NA,Phase 2/Phase 3,120,Actual,Bosnalijek D.D,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:26:22Z,2021-02-01T12:26:22Z,59
NCT04373161,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-30,NA,NA,2020-05-05,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-06,Actual,"March 20, 2020",Actual,2020-03-20,May 2020,2020-05-31,"April 22, 2020",Actual,2020-04-22,"April 22, 2020",Actual,2020-04-22,NA,Interventional,NA,,Home Pulse Oximeter Use in Patients With COVID-19,Utilizing Home Pulse Oximetry for Patients With COVID-19 To Monitor Disease Progression,Completed,NA,N/A,209,Actual,Swedish Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-02-01T12:26:29Z,2021-02-01T12:26:29Z,291
NCT04383535,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-06,NA,NA,2020-09-29,2020-05-08,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-09-30,Actual,"May 15, 2020",Actual,2020-05-15,September 2020,2020-09-30,"September 27, 2020",Actual,2020-09-27,"September 27, 2020",Actual,2020-09-27,NA,Interventional,PLASM-AR,,Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,"Randomized, Double-blind, Placebo-controlled Clinical Trial of Convalescent Plasma for the Treatment of COVID-19 Pneumonia With Severity Criteria",Completed,NA,N/A,333,Actual,Hospital Italiano de Buenos Aires,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:24:45Z,2021-02-01T12:24:45Z,144
NCT04382092,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-06,NA,NA,2020-05-08,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"March 23, 2020",Actual,2020-03-23,May 2020,2020-05-31,"April 24, 2020",Actual,2020-04-24,"April 24, 2020",Actual,2020-04-24,NA,Interventional,NA,,Co-infection Management in COVID-19 Critically Ill,Co-infections in COVID-19 Critically Ill and Antibiotic Management,Completed,NA,N/A,32,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:25:00Z,2021-02-01T12:25:00Z,288
NCT04382066,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-07,NA,NA,2020-12-24,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-12-24,2020-12-28,Actual,"May 12, 2020",Actual,2020-05-12,December 2020,2020-12-31,"December 23, 2020",Actual,2020-12-23,"December 23, 2020",Actual,2020-12-23,NA,Interventional,APLICOV-PC,,Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19,"Multicenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring Hospitalization",Completed,NA,Phase 1,46,Actual,PharmaMar,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,Data of the final publication of the study will be shared upon request.,2021-02-01T12:25:00Z,2021-02-01T12:25:00Z,58
NCT04382053,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-08,NA,NA,2021-01-14,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-14,2021-01-15,Actual,"May 27, 2020",Actual,2020-05-27,January 2021,2021-01-31,"December 24, 2020",Actual,2020-12-24,"December 24, 2020",Actual,2020-12-24,NA,Interventional,NA,,Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia,"Phase 2, Randomized, Controlled, Open Label Multi-center Study to Assess Efficacy and Safety of DFV890 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients With Coronavirus Disease 2019 (COVID-19) Pneumonia and Impaired Respiratory Function",Completed,NA,Phase 2,143,Actual,Novartis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2021-02-01T12:25:00Z,2021-02-01T12:25:00Z,37
NCT04381884,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-05,NA,NA,2020-10-01,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-10-01,2020-10-05,Actual,"May 18, 2020",Actual,2020-05-18,October 2020,2020-10-31,"September 29, 2020",Actual,2020-09-29,"September 29, 2020",Actual,2020-09-29,NA,Interventional,NA,,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,"A Pilot, Proof of Concept Trial to Prove Ivermectin Efficacy in the Reduction of SARS-CoV-2 Replication at Early Stages of COVID-19",Completed,NA,Phase 2,45,Actual,Laboratorio Elea Phoenix S.A.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-02-01T12:25:04Z,2021-02-01T12:25:04Z,142
NCT04381858,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-06,NA,NA,2020-11-26,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-11-26,2020-11-30,Actual,"May 6, 2020",Actual,2020-05-06,May 2020,2020-05-31,"November 26, 2020",Actual,2020-11-26,"November 26, 2020",Actual,2020-11-26,NA,Interventional,NA,,Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia,Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Trial,Completed,NA,Phase 3,196,Actual,Centenario Hospital Miguel Hidalgo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:25:04Z,2021-02-01T12:25:04Z,86
NCT04381000,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-07,NA,NA,2020-06-30,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"April 1, 2020",Actual,2020-04-01,June 2020,2020-06-30,"June 10, 2020",Actual,2020-06-10,"May 29, 2020",Actual,2020-05-29,NA,Interventional,NA,,Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.,The Impact of Quarantine and the Effectiveness of Telerehabilitation in Patients With Chronic Pain During COVID-19 Pandemic.,Completed,NA,N/A,170,Actual,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:25:12Z,2021-02-01T12:25:12Z,235
NCT04380688,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-07,NA,NA,2020-12-01,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-02,Actual,"June 13, 2020",Actual,2020-06-13,November 2020,2020-11-30,"November 16, 2020",Actual,2020-11-16,"November 16, 2020",Actual,2020-11-16,NA,Interventional,CALAVI US,,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19",Completed,NA,Phase 2,62,Actual,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",2021-02-01T12:25:15Z,2021-02-01T12:25:15Z,81
NCT04379531,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-30,NA,NA,2020-06-10,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-12,Actual,"April 25, 2020",Actual,2020-04-25,May 2020,2020-05-31,"May 22, 2020",Actual,2020-05-22,"May 22, 2020",Actual,2020-05-22,NA,Interventional,LDCTiP,,LDCT in COVID-19 Pneumonia: a Prospective Moscow Study,Low-dose Computed Tomography in COVID-19 Pneumonia: a Prospective Moscow Study,Completed,NA,N/A,230,Actual,Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:25:26Z,2021-02-01T12:25:26Z,255
NCT04378803,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-04,NA,NA,2020-08-14,2020-05-04,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-17,Actual,"May 13, 2020",Actual,2020-05-13,August 2020,2020-08-31,"August 4, 2020",Actual,2020-08-04,"August 4, 2020",Actual,2020-08-04,NA,Interventional,NA,,Mindfulness Training for Seniors,Mindfulness Training for Older Adults During the COVID-19 Pandemic,Completed,NA,N/A,53,Actual,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:25:31Z,2021-02-01T12:25:31Z,190
NCT04376814,"ClinicalTrials.gov processed this data on January 29, 2021",2020-05-03,NA,NA,2020-06-12,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-06-12,2020-06-16,Actual,"March 29, 2020",Actual,2020-03-29,May 2020,2020-05-31,"May 25, 2020",Actual,2020-05-25,"April 5, 2020",Actual,2020-04-05,NA,Interventional,NA,,Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19,"The Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir/Ritonavir Plus Hydroxychloroquine Regimen: an Open-label, Non-randomized Clinical Trial Study",Completed,NA,N/A,40,Actual,Baqiyatallah Medical Sciences University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:25:47Z,2021-02-01T12:25:47Z,253
NCT04371965,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-29,NA,NA,2020-10-23,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"September 1, 2020",Actual,2020-09-01,July 2020,2020-07-31,"October 23, 2020",Actual,2020-10-23,"October 23, 2020",Actual,2020-10-23,NA,Interventional,KILLER,,"Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19","Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With SARS-CoV-2",Completed,NA,Phase 2,24,Actual,Poitiers University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:26:39Z,2021-02-01T12:26:39Z,120
NCT04371419,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-28,NA,NA,2020-06-17,2020-04-28,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-17,2020-06-19,Actual,"May 13, 2020",Actual,2020-05-13,June 2020,2020-06-30,"May 24, 2020",Actual,2020-05-24,"May 24, 2020",Actual,2020-05-24,NA,Interventional,NA,,COVID-19 Health Messaging to Underserved Communities,COVID-19 Health Messaging to Underserved Communities,Completed,NA,N/A,15475,Actual,"National Bureau of Economic Research, Inc.",,17,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"Generally, social scientists post code and de-identified data when the findings are published","To be determined, if published alongside the paper data and code may be gated.",NA,Yes,"Generally, economists will post code and de-identified data when the findings are published",2021-02-01T12:26:43Z,2021-02-01T12:26:43Z,248
NCT04370886,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-28,NA,NA,2020-05-28,2020-04-28,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"April 30, 2020",Actual,2020-04-30,April 2020,2020-04-30,"May 10, 2020",Actual,2020-05-10,"April 30, 2020",Actual,2020-04-30,NA,Interventional,NA,,Recruit Blood Donors Via SMS During Epidemic of COVID-19,Recruit Blood Donors Via SMS With Different Contents During Epidemic of COVID-19,Completed,NA,N/A,456517,Actual,Guangzhou Blood Center,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:26:48Z,2021-02-01T12:26:48Z,268
NCT04370782,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-26,NA,NA,2020-12-08,2020-04-29,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-09,Actual,"April 28, 2020",Actual,2020-04-28,December 2020,2020-12-31,"September 30, 2020",Actual,2020-09-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,,Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting,Completed,NA,Phase 4,18,Actual,"St. Francis Hospital, New York",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T12:26:49Z,2021-02-01T12:26:49Z,74
NCT04370262,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-27,NA,NA,2020-12-10,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-12-10,2020-12-11,Actual,"April 7, 2020",Actual,2020-04-07,December 2020,2020-12-31,"September 7, 2020",Actual,2020-09-07,"September 7, 2020",Actual,2020-09-07,NA,Interventional,NA,,Multi-site Adaptive Trials for COVID-19,"A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults",Completed,NA,Phase 3,233,Actual,Northwell Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-02-01T12:26:53Z,2021-02-01T12:26:53Z,72
NCT04368377,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-23,NA,NA,2020-04-28,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"April 23, 2020",Actual,2020-04-23,"April 23, 2020",Actual,2020-04-23,NA,Interventional,PIC-19,,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Platelet Inhibition With GP IIb/IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol,Completed,NA,Phase 2,5,Actual,University of Milan,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T12:27:12Z,2021-02-01T12:27:12Z,298
NCT04367662,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-16,NA,NA,2020-06-05,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 9, 2020",Actual,2020-04-09,June 2020,2020-06-30,"May 14, 2020",Actual,2020-05-14,"May 14, 2020",Actual,2020-05-14,NA,Interventional,COVID'HEMOS,,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Completed,NA,N/A,99,Actual,"University Hospital, Rouen",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:27:18Z,2021-02-01T12:27:18Z,260
NCT04367545,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-27,NA,NA,2020-11-04,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,"April 16, 2020",Actual,2020-04-16,November 2020,2020-11-30,"May 17, 2020",Actual,2020-05-17,"May 17, 2020",Actual,2020-05-17,NA,Interventional,MolCOVID,,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Completed,NA,N/A,130,Actual,"University Hospital, Rouen",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:27:18Z,2021-02-01T12:27:18Z,108
NCT04366947,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-23,NA,NA,2020-12-17,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-12-17,2020-12-19,Actual,"April 14, 2020",Actual,2020-04-14,December 2020,2020-12-31,"October 30, 2020",Actual,2020-10-30,"September 20, 2020",Actual,2020-09-20,NA,Interventional,NA,,Intravascular Access in Suspected/Confirmed COVID-19 Patient,Comparison of Intraosseous Versus Intravenous Access in Suspected/Confirmed COVID-19 Patient in Prehospital Setting,Completed,NA,N/A,60,Actual,Lazarski University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,the investigators will decide after study finishing,2021-02-01T12:27:25Z,2021-02-01T12:27:25Z,65
NCT04366297,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-23,NA,NA,2020-04-27,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"January 12, 2020",Actual,2020-01-12,April 2020,2020-04-30,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Interventional,NA,,Intravascular Access of COVID-19 Patient Under Personal Protective Equipment,Intraosseous Versus Intravenous Access During COVID-19 Patients Performed by Paramedics Wearing Level C Personal Protective Equipment. A Multi-center Prospective Randomized Crossover Single-blinded Simulation Trial,Completed,NA,N/A,41,Actual,Lazarski University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,the investigators will add data into manuscript,2021-02-01T12:27:32Z,2021-02-01T12:27:32Z,299
NCT04365972,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-24,NA,NA,2020-05-06,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 23, 2020",Actual,2020-04-23,May 2020,2020-05-31,"April 30, 2020",Actual,2020-04-30,"April 30, 2020",Actual,2020-04-30,NA,Interventional,NA,,Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic,Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic: An Open Pilot Trial,Completed,NA,N/A,20,Actual,Tel Aviv University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:27:35Z,2021-02-01T12:27:35Z,290
NCT04365738,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-26,NA,NA,2020-04-26,2020-04-26,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-26,2020-04-28,Actual,"March 11, 2020",Actual,2020-03-11,April 2020,2020-04-30,"April 26, 2020",Actual,2020-04-26,"April 10, 2020",Actual,2020-04-10,NA,Interventional,NA,,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection: Prospective Randomized Controlled Trial,Completed,NA,N/A,270,Actual,Istanbul Bilgi University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:27:37Z,2021-02-01T12:27:37Z,300
NCT04365608,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-24,NA,NA,2020-12-17,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-12-17,2020-12-19,Actual,"March 20, 2020",Actual,2020-03-20,December 2020,2020-12-31,"December 10, 2020",Actual,2020-12-10,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,,Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment,Safety and Efficacy of Endotracheal Intubation by Paramedics in Suspected/Confirmed COVID-19 Patients Under Cardiac Arrest Using Vie Scope Laryngoscope,Completed,NA,N/A,90,Actual,Lazarski University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,after manuscript publishing,NA,NA,Yes,NA,2021-02-01T12:27:38Z,2021-02-01T12:27:38Z,65
NCT04365127,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-24,NA,NA,2021-01-25,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"April 27, 2020",Actual,2020-04-27,January 2021,2021-01-31,"August 20, 2020",Actual,2020-08-20,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,,Progesterone for the Treatment of COVID-19 in Hospitalized Men,"A Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized Men",Completed,NA,Phase 1,40,Actual,Cedars-Sinai Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:27:43Z,2021-02-01T12:27:43Z,26
NCT04364594,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-22,NA,NA,2020-07-22,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-22,2020-07-23,Actual,"March 26, 2020",Actual,2020-03-26,July 2020,2020-07-31,"May 30, 2020",Actual,2020-05-30,"April 24, 2020",Actual,2020-04-24,NA,Interventional,COVID-T,,COVID-19 Search in Conjunctival Cells,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Diagnostic Targets for Customized Medicine.,Completed,NA,N/A,50,Actual,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,The data will be available immediately after the statistical analysis of the results and will remain available for at least 1 year,On request by e-mail,NA,Yes,"Study Protocol approved by Ethical Committee, informed consent, clinical study report, will be available",2021-02-01T12:27:47Z,2021-02-01T12:27:47Z,213
NCT04363736,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-21,NA,NA,2020-09-09,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-09-09,2020-09-11,Actual,"May 5, 2020",Actual,2020-05-05,September 2020,2020-09-30,"August 12, 2020",Actual,2020-08-12,"August 12, 2020",Actual,2020-08-12,NA,Interventional,MARIPOSA,,A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,"A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia",Completed,NA,Phase 2,100,Actual,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2021-02-01T12:27:54Z,2021-02-01T12:27:54Z,164
NCT04363593,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-24,NA,NA,2020-12-09,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-12-09,2020-12-10,Actual,"May 4, 2020",Actual,2020-05-04,December 2020,2020-12-31,"November 16, 2020",Actual,2020-11-16,"November 16, 2020",Actual,2020-11-16,NA,Interventional,ROCOCO,,Serology COVID-19 From the Cornwall Hospital Union,Serology COVID-19 From the Cornwall Hospital Union,Completed,NA,N/A,2587,Actual,Centre Hospitalier de Cornouaille,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:27:56Z,2021-02-01T12:27:56Z,73
NCT04362137,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-22,NA,NA,2020-11-10,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"May 2, 2020",Actual,2020-05-02,November 2020,2020-11-30,"October 17, 2020",Actual,2020-10-17,"October 17, 2020",Actual,2020-10-17,NA,Interventional,RUXCOVID,,"Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)","Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)",Completed,NA,Phase 3,432,Actual,Novartis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2021-02-01T12:28:07Z,2021-02-01T12:28:07Z,102
NCT04358614,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-19,NA,NA,2020-04-21,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"March 16, 2020",Actual,2020-03-16,April 2020,2020-04-30,"April 7, 2020",Actual,2020-04-07,"April 5, 2020",Actual,2020-04-05,NA,Interventional,NA,,Baricitinib Therapy in COVID-19,Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact,Completed,NA,Phase 2/Phase 3,12,Actual,Hospital of Prato,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:28:35Z,2021-02-01T12:28:35Z,305
NCT04359251,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-13,NA,NA,2020-04-21,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"March 5, 2020",Actual,2020-03-05,April 2020,2020-04-30,"March 25, 2020",Actual,2020-03-25,"March 25, 2020",Actual,2020-03-25,NA,Interventional,NA,,Different PEEP Settings of COVID-19 Induced ARDS,Avoiding High PEEP in COVID-19 Induced ARDS: a Multi-center Study,Completed,NA,N/A,20,Actual,"Southeast University, China",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:28:31Z,2021-02-01T12:28:31Z,305
NCT04355728,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-13,NA,NA,2020-11-09,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"April 25, 2020",Actual,2020-04-25,November 2020,2020-11-30,"October 31, 2020",Actual,2020-10-31,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,,Use of UC-MSCs for COVID-19 Patients,Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS),Completed,NA,Phase 1/Phase 2,24,Actual,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:29:00Z,2021-02-01T12:29:00Z,103
NCT04358081,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-08,NA,NA,2021-01-13,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-13,2021-01-15,Actual,"May 1, 2020",Actual,2020-05-01,January 2021,2021-01-31,"July 27, 2020",Actual,2020-07-27,"July 27, 2020",Actual,2020-07-27,NA,Interventional,NA,,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,"A Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease",Completed,NA,Phase 3,20,Actual,Novartis,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2021-02-01T12:28:38Z,2021-02-01T12:28:38Z,38
NCT04358068,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-20,NA,NA,2020-07-30,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-07-30,2020-08-03,Actual,"May 1, 2020",Actual,2020-05-01,July 2020,2020-07-31,"July 7, 2020",Actual,2020-07-07,"July 7, 2020",Actual,2020-07-07,NA,Interventional,NA,,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,"A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19",Completed,NA,Phase 2,20,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.,"With whom?
Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
For what types of analyses?
To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
By what mechanism will data be made available?
Researchers may submit a request for access to data using the AIDS Clinical Trials Group ""Data Request"" form at: https://actgnetwork.org/about-actg/templates-and-forms. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.",NA,Yes,"Individual participant data that underlie results in the publication, after deidentification.",2021-02-01T12:28:39Z,2021-02-01T12:28:39Z,205
NCT04357782,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-17,NA,NA,2020-12-21,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-12-21,2020-12-23,Actual,"April 16, 2020",Actual,2020-04-16,December 2020,2020-12-31,"October 13, 2020",Actual,2020-10-13,"October 13, 2020",Actual,2020-10-13,NA,Interventional,AVoCaDO,,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,"Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO): A Phase I/II Safety, Tolerability, and Efficacy Clinical Trial",Completed,NA,Phase 1/Phase 2,20,Actual,Hunter Holmes Mcguire Veteran Affairs Medical Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T12:28:42Z,2021-02-01T12:28:42Z,61
NCT04357340,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-13,NA,NA,2020-05-30,2020-04-18,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-30,2020-06-02,Actual,"April 2, 2020",Actual,2020-04-02,May 2020,2020-05-31,"May 30, 2020",Actual,2020-05-30,"April 30, 2020",Actual,2020-04-30,NA,Interventional,NA,,The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19,Efficacy of Pulmonary Physiotherapy on Hospitalized Patients With Novel Coronavirus 2019 Pneumonia,Completed,NA,N/A,40,Actual,Tehran University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Beginning 3 months and ending 12 months following article publication,Researchers who provide an approved methodologically proposal in the same purpose,NA,Yes,"Individual participant data that underline the results reported in this article, after de-identification",2021-02-01T12:28:45Z,2021-02-01T12:28:45Z,266
NCT04357327,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-15,NA,NA,2020-11-02,2020-04-18,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"April 16, 2020",Actual,2020-04-16,November 2020,2020-11-30,"July 31, 2020",Actual,2020-07-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19): a Diagnostic Accuracy Study,Completed,NA,N/A,122,Actual,UniversitÃ  degli Studi dell'Insubria,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"Data will be available at the end of the study, once statistical analyses is conducted",Contact Principal Investigator,NA,Yes,"We could provide anamnestic, clinical and serological data of each participant at the end of the study, or at least at the end of the first phase.",2021-02-01T12:28:45Z,2021-02-01T12:28:45Z,110
NCT04356937,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-19,NA,NA,2020-12-14,2020-04-19,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-12-14,2020-12-16,Actual,"April 20, 2020",Actual,2020-04-20,December 2020,2020-12-31,"August 27, 2020",Actual,2020-08-27,"July 13, 2020",Actual,2020-07-13,NA,Interventional,NA,,Efficacy of Tocilizumab on Patients With COVID-19,Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19,Completed,NA,Phase 3,243,Actual,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,Request for IPD can be submitted to PI for review,2021-02-01T12:28:48Z,2021-02-01T12:28:48Z,68
NCT04356534,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-15,NA,NA,2020-07-27,2020-04-17,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-28,Actual,"April 19, 2020",Actual,2020-04-19,July 2020,2020-07-31,"July 9, 2020",Actual,2020-07-09,"June 15, 2020",Actual,2020-06-15,NA,Interventional,NA,,Convalescent Plasma Trial in COVID -19 Patients,Use of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia: a Prospective Randomized Trial,Completed,NA,N/A,40,Actual,Royal College of Surgeons in Ireland - Medical University of Bahrain,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"Dr Manaf will act as the data custodian and is responsible for the storage, handling and quality of the study data.
Data will be collected in the case report form to allow for cross referencing to check validity.
Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished. All essential documents including source documents will be retained for a period of 5 years after study completion (last patient, last study point). A label stating the date after which the documents can be destroyed will be placed on the inside front cover of the case notes of trial participants.",Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished.,NA,Yes,"Monitoring, audits, and REC review will be permitted and provide direct access to source data and documents. The Lead PI and the researchers assigned by him will have access to the stored data/specimens. Only the Lead PI and the researchers assigned working on this study will be eligible to obtain the data/specimens from the participants during data collection.",2021-02-01T12:28:51Z,2021-02-01T12:28:51Z,208
NCT04355936,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-17,NA,NA,2020-12-23,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-24,Actual,"May 19, 2020",Actual,2020-05-19,December 2020,2020-12-31,"November 30, 2020",Actual,2020-11-30,"November 2, 2020",Actual,2020-11-02,NA,Interventional,NA,,Telmisartan for Treatment of COVID-19 Patients,Telmisartan for Treatment of COVID-19 Patients: an Open Label Randomized Trial,Completed,NA,Phase 4,400,Actual,Laboratorio Elea Phoenix S.A.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:28:58Z,2021-02-01T12:28:58Z,59
NCT04354870,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-16,NA,NA,2020-10-01,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-10-01,2020-10-05,Actual,"April 3, 2020",Actual,2020-04-03,October 2020,2020-10-31,"October 1, 2020",Actual,2020-10-01,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,,COVID-19 PrEP HCW HCQ Study,Off Label Study to Evaluate the Efficacy of HCQ for Pre-exposure Prophylaxis (PrEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers (HCWs) Who Are at High Risk of Occupational Exposure to SARS-CoV-2,Completed,NA,Phase 2,130,Actual,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,Study internal to NYU at this time,2021-02-01T12:29:08Z,2021-02-01T12:29:08Z,142
NCT04351542,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-14,NA,NA,2020-04-15,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"March 6, 2020",Actual,2020-03-06,April 2020,2020-04-30,"April 12, 2020",Actual,2020-04-12,"April 6, 2020",Actual,2020-04-06,NA,Interventional,NA,,Ayurveda for Flu Like Illness During Covid-19 Outbreak,Ayurveda for Flu-like Illness During the Covid 19 Outbreak: Non Randomised Single-blind Controlled Trial,Completed,NA,N/A,32,Actual,Aarogyam UK,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:29:44Z,2021-02-01T12:29:44Z,311
NCT04350736,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-14,NA,NA,2020-08-31,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"April 23, 2020",Actual,2020-04-23,August 2020,2020-08-31,"June 24, 2020",Actual,2020-06-24,"June 24, 2020",Actual,2020-06-24,NA,Interventional,NA,,"First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19","A Phase 1, Double-blind, Randomized, Placebo-controlled, Sponsor-open, SAD and MAD Study in Healthy Subjects to Evaluate the Safety, Tolerability, and PK of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",Completed,NA,Phase 1,54,Actual,Theravance Biopharma,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.",2021-02-01T12:29:53Z,2021-02-01T12:29:53Z,173
NCT04350281,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-13,NA,NA,2020-07-27,2020-04-13,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-28,Actual,"April 9, 2020",Actual,2020-04-09,July 2020,2020-07-31,"July 7, 2020",Actual,2020-07-07,"July 1, 2020",Actual,2020-07-01,NA,Interventional,NA,,Double Therapy With IFN-beta 1b and Hydroxychloroquine,"An Open-label Randomized Controlled Trial on Interferon Î²-1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 Infection",Completed,NA,Phase 2,60,Actual,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:30:01Z,2021-02-01T12:30:01Z,208
NCT04349410,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-11,NA,NA,2020-11-10,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"April 11, 2020",Actual,2020-04-11,October 2020,2020-10-31,"September 14, 2020",Actual,2020-09-14,"September 14, 2020",Actual,2020-09-14,NA,Interventional,FMTVDM,,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,Completed,NA,Phase 2/Phase 3,1800,Actual,The Camelot Foundation,,11,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,This will depend upon the availability of staff given the multi-nation approach to this project.,Expressed request through email as listed.,NA,Yes,Data will be made available through electronic request from approved individuals and institutions.,2021-02-01T12:30:17Z,2021-02-01T12:30:17Z,102
NCT04350320,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-14,NA,NA,2021-01-11,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-12,Actual,"April 30, 2020",Actual,2020-04-30,January 2021,2021-01-31,"December 30, 2020",Actual,2020-12-30,"October 20, 2020",Actual,2020-10-20,NA,Interventional,COL-COVID,,Trial to Study the Benefit of Colchicine in Patients With COVID-19,"Administration of Colchicine Plus Standard Treatment vs. Standard Therapy, in Hospitalized Patients With COVID-19, Within the First 48 Hours, and no Severity Criteria.",Completed,NA,Phase 3,102,Actual,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T12:30:00Z,2021-02-01T12:30:00Z,40
NCT04349241,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-13,NA,NA,2020-06-24,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-24,2020-06-25,Actual,"April 18, 2020",Actual,2020-04-18,June 2020,2020-06-30,"June 20, 2020",Actual,2020-06-20,"June 1, 2020",Actual,2020-06-01,NA,Interventional,FAV-001,,Efficacy and Safety of Favipiravir in Management of COVID-19,Efficacy and Safety of Favipiravir in Management of COVID-19,Completed,NA,Phase 3,100,Actual,Ain Shams University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:30:18Z,2021-02-01T12:30:18Z,241
NCT04349098,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-14,NA,NA,2020-12-23,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-24,Actual,"April 17, 2020",Actual,2020-04-17,December 2020,2020-12-31,"October 5, 2020",Actual,2020-10-05,"October 5, 2020",Actual,2020-10-05,NA,Interventional,Coronavirus,,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection,Completed,NA,Phase 2,202,Actual,Karyopharm Therapeutics Inc,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:30:19Z,2021-02-01T12:30:19Z,59
NCT04347954,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-13,NA,NA,2021-01-14,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-01-14,2021-01-19,Actual,"August 15, 2020",Actual,2020-08-15,January 2021,2021-01-31,"December 13, 2020",Actual,2020-12-13,"December 13, 2020",Actual,2020-12-13,NA,Interventional,NA,,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers,Completed,NA,Phase 1/Phase 2,40,Actual,Stanford University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T12:30:31Z,2021-02-01T12:30:31Z,37
NCT04347382,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-11,NA,NA,2020-11-09,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"April 30, 2020",Actual,2020-04-30,November 2020,2020-11-30,"August 30, 2020",Actual,2020-08-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,HNS-COVID-PK,,Honey & Nigella Sativa Trial Against COVID-19,"The Role of Honey and Nigella Sativa in the Management of COVID-19; A Randomized Controlled, Open-label, Add-on Trial in Pakistan",Completed,NA,Phase 3,313,Actual,Sheikh Zayed Federal Postgraduate Medical Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:30:35Z,2021-02-01T12:30:35Z,103
NCT04347174,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-31,NA,NA,2021-01-25,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"April 30, 2020",Actual,2020-04-30,January 2021,2021-01-31,"August 21, 2020",Actual,2020-08-21,"August 10, 2020",Actual,2020-08-10,NA,Interventional,NA,,A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients,A Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID 19 Infection,Completed,NA,N/A,40,Actual,Cadila Pharnmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:30:37Z,2021-02-01T12:30:37Z,26
NCT04347031,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-07,NA,NA,2021-01-26,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-27,Actual,"April 8, 2020",Actual,2020-04-08,January 2021,2021-01-31,"November 20, 2020",Actual,2020-11-20,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,,A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,"An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC ""Farmzashita"" of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19",Completed,NA,Phase 2/Phase 3,320,Actual,Burnasyan Federal Medical Biophysical Center,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:30:38Z,2021-02-01T12:30:38Z,25
NCT04346693,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-08,NA,NA,2021-01-26,2020-04-10,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-27,Actual,"April 8, 2020",Actual,2020-04-08,January 2021,2021-01-31,"November 20, 2020",Actual,2020-11-20,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,,An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,An Open Randomized Study of the Effectiveness of the Drug Dalargin for the Prevention and Treatment of Symptoms of Pulmonary Complications in Patients With Coronavirus Infection (SARS-COVID-19),Completed,NA,Phase 3,320,Actual,Burnasyan Federal Medical Biophysical Center,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:30:43Z,2021-02-01T12:30:43Z,25
NCT04346446,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-14,NA,NA,2020-06-11,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-11,2020-06-12,Actual,"April 20, 2020",Actual,2020-04-20,June 2020,2020-06-30,"May 30, 2020",Actual,2020-05-30,"May 30, 2020",Actual,2020-05-30,NA,Interventional,NA,,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients: A Pilot Randomized Controlled Trial,Completed,NA,Phase 2,29,Actual,"Institute of Liver and Biliary Sciences, India",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:30:45Z,2021-02-01T12:30:45Z,254
NCT04346420,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-08,NA,NA,2020-06-05,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 9, 2020",Actual,2020-04-09,June 2020,2020-06-30,"May 1, 2020",Actual,2020-05-01,"May 1, 2020",Actual,2020-05-01,NA,Interventional,NA,,Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19,Impact of the Double-Trunk Mask on Oxygenation Titration in Patients With COVID-19,Completed,NA,N/A,12,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:30:45Z,2021-02-01T12:30:45Z,260
NCT04345549,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-10,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"February 26, 2020",Actual,2020-02-26,April 2020,2020-04-30,"March 30, 2020",Actual,2020-03-30,"March 30, 2020",Actual,2020-03-30,NA,Interventional,NA,,Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak,Ayurveda Self-Management for Flu Like Symptoms in People Self-Isolated for 7 Days During the Coronavirus Disease 2019 (COVID-19) Outbreak,Completed,NA,N/A,18,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:30:52Z,2021-02-01T12:30:52Z,316
NCT04345276,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-10,NA,NA,2020-06-01,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"March 18, 2020",Actual,2020-03-18,March 2020,2020-03-31,"April 15, 2020",Actual,2020-04-15,"April 15, 2020",Actual,2020-04-15,NA,Interventional,NA,,Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,NA,Phase 4,10,Actual,Huoshenshan Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:30:56Z,2021-02-01T12:30:56Z,264
NCT04344210,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-07,NA,NA,2020-10-11,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-11,2020-10-14,Actual,"April 17, 2020",Actual,2020-04-17,October 2020,2020-10-31,"September 20, 2020",Actual,2020-09-20,"September 20, 2020",Actual,2020-09-20,NA,Interventional,NA,,Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus,Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial,Completed,NA,N/A,149,Actual,Federal University of Rio Grande do Sul,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-02-01T12:31:04Z,2021-02-01T12:31:04Z,132
NCT04343092,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-05,2020-06-11,NA,2020-11-02,2020-04-08,2020-04-13,Actual,2020-11-02,2020-11-04,Actual,NA,NA,NA,2020-11-02,2020-11-04,Actual,"April 18, 2020",Actual,2020-04-18,November 2020,2020-11-30,"June 1, 2020",Actual,2020-06-01,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (An Externally Controlled Pilot Trial),Completed,NA,Phase 1,16,Actual,University of Baghdad,"small sample size; single center design, and short time for the study",1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:31:15Z,2021-02-01T12:31:15Z,110
NCT04343768,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-08,NA,NA,2020-05-02,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-02,2020-05-05,Actual,"April 9, 2020",Actual,2020-04-09,May 2020,2020-05-31,"April 27, 2020",Actual,2020-04-27,"April 27, 2020",Actual,2020-04-27,NA,Interventional,COVIFERON,,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Completed,NA,Phase 2,60,Actual,Shahid Beheshti University of Medical Sciences,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,One year after the publication of the results in a journal.,"Qualifying researchers who reach out to Dr. Seyed Sina Naghibi Irvani at ""sina.irvani@sbmu.ac.ir"" or ""sina.irvani@gmail.com"" and submit a proposal with a valuable research question.",NA,Yes,"One year after the publication of the results in a journal, Qualifying researchers who reach out to Dr. Seyed Sina Naghibi Irvani at ""sina.irvani@sbmu.ac.ir"" or ""sina.irvani@gmail.com"" and submit a proposal with a valuable research question can have access to data and supporting information.",2021-02-01T12:31:10Z,2021-02-01T12:31:10Z,294
NCT04343261,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-08,2020-09-01,NA,2020-09-22,2020-04-08,2020-04-13,Actual,2020-09-15,2020-09-17,Actual,NA,NA,NA,2020-09-22,2020-09-24,Actual,"April 10, 2020",Actual,2020-04-10,September 2020,2020-09-30,"August 13, 2020",Actual,2020-08-13,"July 23, 2020",Actual,2020-07-23,NA,Interventional,NA,,Convalescent Plasma in the Treatment of COVID 19,Convalescent Plasma in the Treatment of COVID 19,Completed,NA,Phase 2,48,Actual,Saint Francis Care,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:31:14Z,2021-02-01T12:31:14Z,151
NCT04342663,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-08,NA,NA,2021-01-08,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"April 10, 2020",Actual,2020-04-10,January 2021,2021-01-31,"December 12, 2020",Actual,2020-12-12,"August 20, 2020",Actual,2020-08-20,NA,Interventional,STOP COVID,,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",Completed,NA,Phase 2,152,Actual,Washington University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-02-01T12:31:19Z,2021-02-01T12:31:19Z,43
NCT04342650,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-04,NA,NA,2020-07-02,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-07-02,2020-07-07,Actual,"April 8, 2020",Actual,2020-04-08,July 2020,2020-07-31,"June 8, 2020",Actual,2020-06-08,"May 14, 2020",Actual,2020-05-14,NA,Interventional,CloroCOVID19II,,Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,"Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial",Completed,NA,Phase 2,152,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,after study publication,Upon formal request to researchers.,NA,Yes,all patient data will be shared after study publication,2021-02-01T12:31:19Z,2021-02-01T12:31:19Z,233
NCT04340050,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-07,NA,NA,2020-12-23,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-28,Actual,"April 10, 2020",Actual,2020-04-10,December 2020,2020-12-31,"December 23, 2020",Actual,2020-12-23,"December 23, 2020",Actual,2020-12-23,NA,Interventional,NA,,COVID-19 Convalescent Plasma,Pilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical Center,Completed,NA,Early Phase 1,10,Actual,University of Chicago,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Upon publication of the major manuscript to be generated from this study. Data will be deposited in an appropriate major database,NA,NA,Yes,We will share individual participant data that is de-identified available to all qualified investigators,2021-02-01T12:31:47Z,2021-02-01T12:31:47Z,59
NCT04339712,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-01,NA,NA,2021-01-08,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"April 2, 2020",Actual,2020-04-02,January 2021,2021-01-31,"January 8, 2021",Actual,2021-01-08,"December 1, 2020",Actual,2020-12-01,NA,Interventional,ESCAPE,,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial,Completed,NA,Phase 2,102,Actual,Hellenic Institute for the Study of Sepsis,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:31:51Z,2021-02-01T12:31:51Z,43
NCT04338841,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-05,NA,NA,2020-09-22,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-23,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"June 17, 2020",Actual,2020-06-17,"June 17, 2020",Actual,2020-06-17,NA,Interventional,HOME-CoV,,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With Confirmed or Probable SARS-CoV-2 Infection. A Before and After Implementation of a Consensus Help-decision Making Rule Study,Completed,NA,N/A,3133,Actual,"University Hospital, Angers",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:31:58Z,2021-02-01T12:31:58Z,151
NCT04337541,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-02,NA,NA,2020-07-29,2020-04-05,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-08-03,Actual,"April 2, 2020",Actual,2020-04-02,July 2020,2020-07-31,"June 2, 2020",Actual,2020-06-02,"June 2, 2020",Actual,2020-06-02,NA,Interventional,NA,,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Completed,NA,N/A,6000,Actual,"Rigshospitalet, Denmark",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:32:23Z,2021-02-01T12:32:23Z,206
NCT04335851,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-02,NA,NA,2020-06-04,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-09,Actual,"April 6, 2020",Actual,2020-04-06,June 2020,2020-06-30,"June 3, 2020",Actual,2020-06-03,"May 15, 2020",Actual,2020-05-15,NA,Interventional,NA,,Video-Based Exercises and Well-Being During Social Isolation,Effectiveness of Video-Based Exercises on Physical and Emotional Well-Being During COVID-19 Induced Social Isolation,Completed,NA,N/A,68,Actual,Biruni University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:32:36Z,2021-02-01T12:32:36Z,261
NCT04335136,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-01,NA,NA,2021-01-21,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-22,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,"December 26, 2020",Actual,2020-12-26,"December 26, 2020",Actual,2020-12-26,NA,Interventional,APN01-COVID-19,,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Completed,NA,Phase 2,200,Actual,Apeiron Biologics,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:32:42Z,2021-02-01T12:32:42Z,30
NCT04335123,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-31,NA,NA,2020-11-02,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"April 4, 2020",Actual,2020-04-04,November 2020,2020-11-30,"August 17, 2020",Actual,2020-08-17,"June 21, 2020",Actual,2020-06-21,NA,Interventional,NA,,Study of Open Label Losartan in COVID-19,An Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19,Completed,NA,Phase 1,34,Actual,University of Kansas Medical Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T12:32:42Z,2021-02-01T12:32:42Z,110
NCT04335279,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-01,NA,NA,2020-11-26,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-26,2020-11-30,Actual,"April 9, 2020",Actual,2020-04-09,November 2020,2020-11-30,"July 24, 2020",Actual,2020-07-24,"June 3, 2020",Actual,2020-06-03,NA,Interventional,SPIN-CHAT,,Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program,A Partially Nested RCT to Evaluate the Effectiveness of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program to Reduce Anxiety Among At-Risk Scleroderma Patients,Completed,NA,N/A,172,Actual,Lady Davis Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,12 months after the collection of the primary outcome,Approval of proposed purpose for data access,NA,Yes,Upon request,2021-02-01T12:32:41Z,2021-02-01T12:32:41Z,86
NCT04332991,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-31,NA,NA,2020-09-01,2020-03-31,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-02,Actual,"April 2, 2020",Actual,2020-04-02,September 2020,2020-09-30,"July 23, 2020",Actual,2020-07-23,"June 19, 2020",Actual,2020-06-19,NA,Interventional,ORCHID,,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Completed,NA,Phase 3,479,Actual,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-01T12:33:08Z,2021-02-01T12:33:08Z,172
NCT04333225,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-01,NA,NA,2021-01-25,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-26,Actual,"April 3, 2020",Actual,2020-04-03,May 2020,2020-05-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures,Completed,NA,Phase 2,228,Actual,Baylor Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T12:33:03Z,2021-02-01T12:33:03Z,26
NCT04332835,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-31,NA,NA,2020-11-25,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-27,Actual,"August 8, 2020",Actual,2020-08-08,November 2020,2020-11-30,"November 15, 2020",Actual,2020-11-15,"October 31, 2020",Actual,2020-10-31,NA,Interventional,CP-COVID-19,,"Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study","Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study",Completed,NA,Phase 2/Phase 3,92,Actual,Universidad del Rosario,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:33:09Z,2021-02-01T12:33:09Z,87
NCT04332380,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-30,NA,NA,2020-08-12,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-17,Actual,"May 1, 2020",Actual,2020-05-01,August 2020,2020-08-31,"July 28, 2020",Actual,2020-07-28,"July 28, 2020",Actual,2020-07-28,NA,Interventional,CP-COVID-19,,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Completed,NA,Phase 2,10,Actual,Universidad del Rosario,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:33:13Z,2021-02-01T12:33:13Z,192
NCT04331795,"ClinicalTrials.gov processed this data on January 29, 2021",2020-04-01,NA,NA,2020-07-30,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-07-30,2020-08-03,Actual,"April 4, 2020",Actual,2020-04-04,June 2020,2020-06-30,"June 5, 2020",Actual,2020-06-05,"June 5, 2020",Actual,2020-06-05,NA,Interventional,COVIDOSE,,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis,Completed,NA,Phase 2,32,Actual,University of Chicago,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T12:33:18Z,2021-02-01T12:33:18Z,205
NCT04329533,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-26,NA,NA,2020-11-11,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Actual,"April 13, 2020",Actual,2020-04-13,November 2020,2020-11-30,"November 1, 2020",Actual,2020-11-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,,Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic,Effects of a Mobile Meditation App on Stress During COVID-19 Pandemic in Outpatient Obstetrics and Gynecology Patients; a Randomized Controlled Trial,Completed,NA,N/A,101,Actual,University of Arizona,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T12:33:43Z,2021-02-01T12:33:43Z,101
NCT04328961,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-23,NA,NA,2020-10-27,2020-03-29,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-29,Actual,"March 31, 2020",Actual,2020-03-31,October 2020,2020-10-31,"October 8, 2020",Actual,2020-10-08,"September 24, 2020",Actual,2020-09-24,NA,Interventional,NA,,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),"Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study",Completed,NA,Phase 2/Phase 3,829,Actual,University of Washington,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,Within 3 months of publication of primary results.,De-identified data from the study will be made available in accordance with the funder's open access policy.,https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy,Yes,De-identified data from the study will be made available in accordance with the funder's open access policy.,2021-02-01T12:33:47Z,2021-02-01T12:33:47Z,116
NCT04327388,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-26,NA,NA,2020-09-28,2020-03-26,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"March 28, 2020",Actual,2020-03-28,September 2020,2020-09-30,"September 2, 2020",Actual,2020-09-02,"July 30, 2020",Actual,2020-07-30,NA,Interventional,NA,,Sarilumab COVID-19,"An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19",Completed,NA,Phase 3,420,Actual,Sanofi,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-02-01T12:34:00Z,2021-02-01T12:34:00Z,145
NCT04324489,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-25,NA,NA,2020-05-01,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-01,2020-05-05,Actual,"March 6, 2020",Actual,2020-03-06,May 2020,2020-05-31,"April 30, 2020",Actual,2020-04-30,"April 16, 2020",Actual,2020-04-16,NA,Interventional,NA,,DAS181 for Severe COVID-19: Compassionate Use,DAS181 for Severe COVID-19: Compassionate Use,Completed,NA,N/A,4,Actual,Renmin Hospital of Wuhan University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-02-01T12:34:25Z,2021-02-01T12:34:25Z,295
NCT04323527,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-19,NA,NA,2020-07-02,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-07-02,2020-07-07,Actual,"March 23, 2020",Actual,2020-03-23,July 2020,2020-07-31,"June 7, 2020",Actual,2020-06-07,"May 7, 2020",Actual,2020-05-07,NA,Interventional,CloroCOVID19,,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,"Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial",Completed,NA,Phase 2,278,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,after study publication,upon request to researchers,NA,Yes,all patient data will be shared after study publication,2021-02-01T12:34:35Z,2021-02-01T12:34:35Z,233
NCT04322682,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-23,NA,NA,2021-01-21,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-25,Actual,"March 23, 2020",Actual,2020-03-23,January 2021,2021-01-31,"January 21, 2021",Actual,2021-01-21,"January 21, 2021",Actual,2021-01-21,NA,Interventional,COVID-19,,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Completed,NA,Phase 3,4506,Actual,Montreal Heart Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-02-01T12:34:43Z,2021-02-01T12:34:43Z,30
NCT04321421,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-23,NA,NA,2020-05-27,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-28,Actual,"March 17, 2020",Actual,2020-03-17,May 2020,2020-05-31,"May 7, 2020",Actual,2020-05-07,"April 28, 2020",Actual,2020-04-28,NA,Interventional,COV19-PLASMA,,Hyperimmune Plasma for Critical Patients With COVID-19,Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19,Completed,NA,N/A,49,Actual,Foundation IRCCS San Matteo Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,will be decided,2021-02-01T12:34:56Z,2021-02-01T12:34:56Z,269
NCT04321278,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-23,NA,NA,2021-01-15,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-01-15,2021-01-20,Actual,"March 28, 2020",Actual,2020-03-28,March 2020,2020-03-31,"June 14, 2020",Actual,2020-06-14,"June 14, 2020",Actual,2020-06-14,NA,Interventional,NA,,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - SEVERE - Patients,Completed,NA,Phase 3,440,Actual,Hospital Israelita Albert Einstein,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-01T12:34:57Z,2021-02-01T12:34:57Z,36
NCT04320615,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-23,NA,NA,2020-09-23,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"April 3, 2020",Actual,2020-04-03,September 2020,2020-09-30,"July 28, 2020",Actual,2020-07-28,"June 24, 2020",Actual,2020-06-24,NA,Interventional,COVACTA,,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia",Completed,NA,Phase 3,450,Actual,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform https://vivli.org.
Further details on Roche's criteria for eligible studies are available here: https://vivli.org.
For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm",2021-02-01T12:35:03Z,2021-02-01T12:35:03Z,150
NCT04318431,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-20,NA,NA,2020-07-08,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-08,2020-07-09,Actual,"April 14, 2020",Actual,2020-04-14,July 2020,2020-07-31,"June 1, 2020",Actual,2020-06-01,"May 12, 2020",Actual,2020-05-12,NA,Interventional,COVILLE,,Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children,"Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children, a Cross-sectional, Prospective, Multicentre, Observational Study in Primary Care.",Completed,NA,N/A,605,Actual,Centre Hospitalier Intercommunal Creteil,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:35:30Z,2021-02-01T12:35:30Z,227
NCT04315298,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-15,NA,NA,2020-09-30,2020-03-17,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-01,Actual,"March 18, 2020",Actual,2020-03-18,September 2020,2020-09-30,"September 2, 2020",Actual,2020-09-02,"July 24, 2020",Actual,2020-07-24,NA,Interventional,NA,,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,"An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19",Completed,NA,Phase 2/Phase 3,1912,Actual,Regeneron Pharmaceuticals,,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All IPD that underlie publicly available results will be considered for sharing,2021-02-01T12:35:58Z,2021-02-01T12:35:58Z,143
NCT04308668,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-11,NA,NA,2020-07-15,2020-03-11,2020-03-16,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-17,Actual,"March 17, 2020",Actual,2020-03-17,July 2020,2020-07-31,"May 20, 2020",Actual,2020-05-20,"May 20, 2020",Actual,2020-05-20,NA,Interventional,COVID-19 PEP,,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Completed,NA,Phase 3,1309,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,at time of publication,To be publicly provided,http://covidpep.umn.edu,Yes,De-identified dataset will be available within 1 month of publication.,2021-02-01T12:37:12Z,2021-02-01T12:37:12Z,220
NCT04304053,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-05,NA,NA,2020-06-26,2020-03-07,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-26,2020-06-30,Actual,"March 18, 2020",Actual,2020-03-18,June 2020,2020-06-30,"June 15, 2020",Actual,2020-06-15,"June 15, 2020",Actual,2020-06-15,NA,Interventional,HCQ4COV19,,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study),Completed,NA,Phase 3,2300,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,30 days after start of treatment,Open access for everybody,http://www.estudicovid19.org,Yes,Open access,2021-02-01T12:38:01Z,2021-02-01T12:38:01Z,239
NCT04306055,"ClinicalTrials.gov processed this data on January 29, 2021",2020-03-08,NA,NA,2020-04-09,2020-03-10,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"March 13, 2020",Actual,2020-03-13,April 2020,2020-04-30,"April 3, 2020",Actual,2020-04-03,"March 13, 2020",Actual,2020-03-13,NA,Interventional,NA,,Blood Donor Recruitment During Epidemic of COVID-19,"Blood Donor Recruitment During Epidemic of COVID-19 in Guangzhou, China",Completed,NA,N/A,19491,Actual,Guangzhou Blood Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:37:36Z,2021-02-01T12:37:36Z,317
NCT04292899,"ClinicalTrials.gov processed this data on January 29, 2021",2020-02-28,2020-12-15,NA,2020-12-15,2020-02-28,2020-03-03,Actual,2020-12-15,2020-12-31,Actual,NA,NA,NA,2020-12-15,2020-12-31,Actual,"March 6, 2020",Actual,2020-03-06,December 2020,2020-12-31,"June 30, 2020",Actual,2020-06-30,"April 9, 2020",Actual,2020-04-09,NA,Interventional,NA,"Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment.
Part B: Expanded RDV-Treated Analysis Set included participants who were enrolled into part B of the study and received at least 1 dose of study treatment.",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe COVID-19,Completed,NA,Phase 3,4891,Actual,Gilead Sciences,,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,Yes,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2021-02-01T12:39:59Z,2021-02-01T12:39:59Z,67
NCT04292730,"ClinicalTrials.gov processed this data on January 29, 2021",2020-02-28,2020-12-15,NA,2021-01-21,2020-02-28,2020-03-03,Actual,2021-01-21,2021-01-26,Actual,NA,NA,NA,2021-01-21,2021-01-26,Actual,"March 15, 2020",Actual,2020-03-15,January 2021,2021-01-31,"June 26, 2020",Actual,2020-06-26,"April 29, 2020",Actual,2020-04-29,NA,Interventional,NA,"Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment or completed the Day 1 visit (SOC only group).
Part B: Expanded RDV-Treated Analysis Set included participants who were enrolled into Part B of the study and received at least 1 dose of study drug.",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment,Completed,NA,Phase 3,1113,Actual,Gilead Sciences,,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,Yes,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2021-02-01T12:40:06Z,2021-02-01T12:40:06Z,30
NCT04291729,"ClinicalTrials.gov processed this data on January 29, 2021",2020-02-27,NA,NA,2020-04-09,2020-02-28,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"February 17, 2020",Actual,2020-02-17,March 2020,2020-03-31,"March 19, 2020",Actual,2020-03-19,"March 19, 2020",Actual,2020-03-19,NA,Interventional,NA,,Evaluation of Ganovo ï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,An Open Clinical Trial to Evaluate Ganovoï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,NA,Phase 4,11,Actual,The Ninth Hospital of Nanchang,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:40:20Z,2021-02-01T12:40:20Z,317
NCT04288102,"ClinicalTrials.gov processed this data on January 29, 2021",2020-02-24,NA,NA,2020-08-18,2020-02-25,2020-02-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"March 5, 2020",Actual,2020-03-05,August 2020,2020-08-31,"July 9, 2020",Actual,2020-07-09,"May 12, 2020",Actual,2020-05-12,NA,Interventional,NA,,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),"A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Severe COVID-19 Patients",Completed,NA,Phase 2,100,Actual,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"After approval from the steering committee and the Human Genetic Resources Administration of China, this trial data can be shared with qualifying researchers who submit a proposal with a valuable research question. A contract should be signed.",2021-02-01T12:40:55Z,2021-02-01T12:40:55Z,186
NCT04280705,"ClinicalTrials.gov processed this data on January 29, 2021",2020-02-20,2020-09-16,NA,2020-12-05,2020-02-20,2020-02-21,Actual,2020-09-22,2020-09-25,Actual,NA,NA,NA,2020-12-05,2020-12-09,Actual,"February 21, 2020",Actual,2020-02-21,April 2020,2020-04-30,"May 21, 2020",Actual,2020-05-21,"May 21, 2020",Actual,2020-05-21,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial (ACTT),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults",Completed,NA,Phase 3,1062,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-02-01T12:42:11Z,2021-02-01T12:42:11Z,77
NCT04276987,"ClinicalTrials.gov processed this data on January 29, 2021",2020-02-16,NA,NA,2020-09-03,2020-02-18,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-03,2020-09-07,Actual,"February 15, 2020",Actual,2020-02-15,September 2020,2020-09-30,"July 31, 2020",Actual,2020-07-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia,Completed,NA,Phase 1,24,Actual,Ruijin Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,Starting 6 months after publication,NA,NA,Yes,all IPD that underlie results in a publication,2021-02-01T12:42:52Z,2021-02-01T12:42:52Z,170
NCT04276688,"ClinicalTrials.gov processed this data on January 29, 2021",2020-02-11,NA,NA,2020-04-13,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"February 10, 2020",Actual,2020-02-10,April 2020,2020-04-30,"March 31, 2020",Actual,2020-03-31,"March 30, 2020",Actual,2020-03-30,NA,Interventional,NA,,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection",Completed,NA,Phase 2,127,Actual,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:42:56Z,2021-02-01T12:42:56Z,313
NCT04275414,"ClinicalTrials.gov processed this data on January 29, 2021",2020-02-14,NA,NA,2020-09-10,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-14,Actual,"February 15, 2020",Actual,2020-02-15,February 2020,2020-02-29,"May 2, 2020",Actual,2020-05-02,"April 5, 2020",Actual,2020-04-05,NA,Interventional,BEST-CP,,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,Effecacy and Safety of Bevacizumab in Severe Patients With Covid-19: a Pilot Study (BEST-CP),Completed,NA,Phase 2,27,Actual,Qilu Hospital of Shandong University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:43:09Z,2021-02-01T12:43:09Z,163
NCT04273321,"ClinicalTrials.gov processed this data on January 29, 2021",2020-02-15,NA,NA,2020-05-08,2020-02-17,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"February 14, 2020",Actual,2020-02-14,April 2020,2020-04-30,"April 15, 2020",Actual,2020-04-15,"April 15, 2020",Actual,2020-04-15,NA,Interventional,NA,,Efficacy and Safety of Corticosteroids in COVID-19,Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails,Completed,NA,N/A,86,Actual,Beijing Chao Yang Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-02-01T12:43:33Z,2021-02-01T12:43:33Z,288
NCT04261517,"ClinicalTrials.gov processed this data on January 29, 2021",2020-02-06,NA,NA,2020-04-09,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"February 6, 2020",Actual,2020-02-06,April 2020,2020-04-30,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Interventional,NA,,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Completed,NA,Phase 3,30,Actual,Shanghai Public Health Clinical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-01T12:46:24Z,2021-02-01T12:46:24Z,317
NCT04252885,"ClinicalTrials.gov processed this data on January 29, 2021",2020-01-30,NA,NA,2020-06-29,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-06-29,2020-07-01,Actual,"January 28, 2020",Actual,2020-01-28,June 2020,2020-06-30,"May 31, 2020",Actual,2020-05-31,"April 30, 2020",Actual,2020-04-30,NA,Interventional,ELACOI,,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,"A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection",Completed,NA,Phase 4,86,Actual,Guangzhou 8th People's Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-02-01T12:48:18Z,2021-02-01T12:48:18Z,236
NCT04244591,"ClinicalTrials.gov processed this data on January 29, 2021",2020-01-23,NA,NA,2020-06-13,2020-01-25,2020-01-28,Actual,NA,NA,NA,NA,NA,NA,2020-06-13,2020-06-16,Actual,"January 26, 2020",Actual,2020-01-26,February 2020,2020-02-29,"April 13, 2020",Actual,2020-04-13,"April 13, 2020",Actual,2020-04-13,NA,Interventional,NA,,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,"Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial",Completed,NA,Phase 2/Phase 3,80,Actual,Peking Union Medical College Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-01T12:50:11Z,2021-02-01T12:50:11Z,252
NCT04730323,"ClinicalTrials.gov processed this data on February 01, 2021",2021-01-26,NA,NA,2021-01-28,2021-01-28,2021-01-29,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"May 12, 2020",Actual,2020-05-12,January 2021,2021-01-31,"June 12, 2020",Actual,2020-06-12,"June 12, 2020",Actual,2020-06-12,NA,Interventional,NA,,TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience,TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience,Completed,NA,Phase 4,93,Actual,FMH College of Medicine and Dentistry,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,"Whenever will be asked to, within few days",Only officials can access the data,NA,Yes,IPD can be shared with researchers in future too,2021-02-02T12:31:15Z,2021-02-02T12:31:15Z,23
NCT04459962,"ClinicalTrials.gov processed this data on February 01, 2021",2020-07-03,NA,NA,2021-01-28,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"June 29, 2020",Actual,2020-06-29,July 2020,2020-07-31,"January 7, 2021",Actual,2021-01-07,"January 7, 2021",Actual,2021-01-07,NA,Interventional,NA,,Covid-19 Breath Test,Breath Test Feasibility Trial for Covid-19 Infection Diagnosis,Completed,NA,N/A,330,Actual,Ancon Technologies Ltd,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-02T12:35:15Z,2021-02-02T12:35:15Z,23
NCT04412668,"ClinicalTrials.gov processed this data on February 01, 2021",2020-06-01,NA,NA,2021-01-28,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"June 12, 2020",Actual,2020-06-12,January 2021,2021-01-31,"December 21, 2020",Actual,2020-12-21,"December 21, 2020",Actual,2020-12-21,NA,Interventional,NA,,Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19,A Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19),Completed,NA,Phase 2,32,Actual,"aTyr Pharma, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-02T12:35:45Z,2021-02-02T12:35:45Z,23
NCT04734171,"ClinicalTrials.gov processed this data on February 04, 2021",2021-01-29,NA,NA,2021-02-01,2021-02-01,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-02,Actual,"April 2, 2020",Actual,2020-04-02,February 2021,2021-02-28,"April 16, 2020",Actual,2020-04-16,"April 16, 2020",Actual,2020-04-16,NA,Interventional,NA,,"Social Activity, Loneliness and Stigma During COVID-19 Outbreak","COVID-19 and Its Implications on Social Activity, Loneliness and Stigma",Completed,NA,N/A,1200,Actual,Columbia University,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-05T12:29:01Z,2021-02-05T12:29:01Z,19
NCT04733625,"ClinicalTrials.gov processed this data on February 04, 2021",2021-01-31,NA,NA,2021-01-31,2021-01-31,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-31,2021-02-02,Actual,"September 15, 2020",Actual,2020-09-15,January 2021,2021-01-31,"December 17, 2020",Actual,2020-12-17,"December 17, 2020",Actual,2020-12-17,NA,Interventional,NA,,The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection,The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection,Completed,NA,N/A,56,Actual,Kasr El Aini Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-05T12:29:18Z,2021-02-05T12:29:18Z,20
NCT04728594,"ClinicalTrials.gov processed this data on February 04, 2021",2021-01-26,NA,NA,2021-01-27,2021-01-26,2021-01-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-27,2021-02-01,Actual,"January 15, 2021",Actual,2021-01-15,January 2021,2021-01-31,"January 20, 2021",Actual,2021-01-20,"January 17, 2021",Actual,2021-01-17,NA,Interventional,NA,,Emails Promoting COVID-19 Vaccination Among Healthcare Workers,Evaluation of an Email Intervention Promoting COVID-19 Vaccination Among Healthcare Workers,Completed,NA,N/A,9656,Actual,Geisinger Clinic,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,The data will become available after publication of study results in a scientific journal and will be available as long as the Open Science Framework hosts the data.,The data on the Open Science Framework will be open to anyone requesting that information.,http://osf.io,Yes,Data with no personally identifiable information will be made available to other researchers on the Open Science Framework for transparency. This will include the essential data and code needed to replicate the analysis that yielded reported findings.,2021-02-05T12:31:05Z,2021-02-05T12:31:05Z,24
NCT04723290,"ClinicalTrials.gov processed this data on February 04, 2021",2021-01-21,NA,NA,2021-01-27,2021-01-21,2021-01-25,Actual,NA,NA,NA,NA,NA,NA,2021-01-27,2021-02-01,Actual,"June 20, 2020",Actual,2020-06-20,January 2021,2021-01-31,"December 31, 2020",Actual,2020-12-31,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,,COVID-19 Seroconversion Study Among GHdC Staff Members - Summer 2020,SARS-CoV-2 Seroconversion Study Among GHdC Staff Members,Completed,NA,N/A,4000,Actual,Grand HÃ´pital de Charleroi,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"At this moment, there is no plan to share the results",2021-02-05T12:31:24Z,2021-02-05T12:31:24Z,24
NCT04674644,"ClinicalTrials.gov processed this data on February 04, 2021",2020-12-16,2021-01-02,NA,2021-01-30,2020-12-17,2020-12-19,Actual,2021-01-27,2021-01-29,Actual,NA,NA,NA,2021-01-30,2021-02-02,Actual,"October 16, 2020",Actual,2020-10-16,January 2021,2021-01-31,"October 23, 2020",Actual,2020-10-23,"October 23, 2020",Actual,2020-10-23,NA,Interventional,NA,,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Suleyman Demirel University Faculty of Dentistry Pediatric Dentistry Department,Completed,NA,N/A,850,Actual,Suleyman Demirel University,"The present study has some limitations. Since the stress and anxiety levels of the dentists participating in the study prior to the pandemic are not known, the extent of the increase in these levels is unknown. In addition, because this is a cross-sectional study, the findings reflect only a certain period of the pandemic. Only scales related to COVID-19 were included, as it was thought that participants might be reluctant to participate in a longer survey.",1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-05T12:32:56Z,2021-02-05T12:32:56Z,21
NCT04623021,"ClinicalTrials.gov processed this data on February 04, 2021",2020-11-05,NA,NA,2021-01-31,2020-11-09,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2021-01-31,2021-02-02,Actual,"September 25, 2020",Actual,2020-09-25,January 2021,2021-01-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,,A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,"An Open-label, Randomized, Multicenter, Controlled Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia",Completed,NA,Phase 2,104,Actual,Chong Kun Dang Pharmaceutical,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-05T12:34:27Z,2021-02-05T12:34:27Z,20
NCT04548934,"ClinicalTrials.gov processed this data on February 04, 2021",2020-09-02,NA,NA,2021-02-01,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-02,Actual,"September 13, 2020",Actual,2020-09-13,September 2020,2020-09-30,"January 31, 2021",Actual,2021-01-31,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,,Effect of Wearing Personal Protective Equipment (PPE) on CPR Quality in Times of the COVID-19-pandemic,Effect of Wearing Personal Protective Equipment (PPE) on CPR Quality in Times of the COVID-19-pandemic,Completed,NA,N/A,34,Actual,Institute of Mountain Emergency Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-05T12:36:42Z,2021-02-05T12:36:42Z,19
NCT04498442,"ClinicalTrials.gov processed this data on February 04, 2021",2020-08-03,NA,NA,2021-01-28,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-02-01,Actual,"May 22, 2020",Actual,2020-05-22,January 2021,2021-01-31,"October 22, 2020",Actual,2020-10-22,"October 22, 2020",Actual,2020-10-22,NA,Interventional,NA,,"A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls","A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls",Completed,NA,N/A,8519,Actual,Beth Israel Deaconess Medical Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-05T12:38:03Z,2021-02-05T12:38:03Z,23
NCT04346199,"ClinicalTrials.gov processed this data on February 04, 2021",2020-04-09,NA,NA,2021-02-01,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-02,Actual,"June 12, 2020",Actual,2020-06-12,January 2021,2021-01-31,"November 17, 2020",Actual,2020-11-17,"November 17, 2020",Actual,2020-11-17,NA,Interventional,CALAVI,,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19",Completed,NA,Phase 2,177,Actual,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.,2021-02-05T12:41:32Z,2021-02-05T12:41:32Z,19
NCT04341584,"ClinicalTrials.gov processed this data on February 04, 2021",2020-04-07,NA,NA,2021-01-29,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2021-01-29,2021-02-01,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"July 25, 2020",Actual,2020-07-25,"May 10, 2020",Actual,2020-05-10,NA,Interventional,CORIMUNO-ANA,,CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection,"CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection, Nested In The CORIMUNO-19",Completed,NA,Phase 2,161,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-05T12:41:38Z,2021-02-05T12:41:38Z,22
NCT04525417,"ClinicalTrials.gov processed this data on February 05, 2021",2020-08-21,NA,NA,2021-02-02,2020-08-22,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-03,Actual,"April 25, 2020",Actual,2020-04-25,August 2020,2020-08-31,"October 25, 2020",Actual,2020-10-25,"September 25, 2020",Actual,2020-09-25,NA,Interventional,NA,,Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers,Use of Rapid Covid-19 Antibody Test Marketed by AAZ Laboratories in Healthcare Workers Presumably Being Infected by SARS-CoV-2,Completed,NA,N/A,75,Actual,Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-07T10:46:16Z,2021-02-07T10:46:16Z,18
NCT04511949,"ClinicalTrials.gov processed this data on February 05, 2021",2020-08-12,NA,NA,2021-02-02,2020-08-12,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-03,Actual,"July 12, 2020",Actual,2020-07-12,February 2021,2021-02-28,"November 30, 2020",Actual,2020-11-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,FAMICOV,,COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Completed,NA,N/A,500,Actual,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-07T10:46:28Z,2021-02-07T10:46:28Z,18
NCT04446429,"ClinicalTrials.gov processed this data on February 05, 2021",2020-06-22,2021-01-22,NA,2021-01-29,2020-06-23,2020-06-24,Actual,2021-01-29,2021-02-03,Actual,NA,NA,NA,2021-01-29,2021-02-03,Actual,"September 15, 2020",Actual,2020-09-15,January 2021,2021-01-31,"January 21, 2021",Actual,2021-01-21,"December 24, 2020",Actual,2020-12-24,NA,Interventional,NA,,Anti-Androgen Treatment for COVID-19,Anti-Androgen Treatment for COVID-19,Completed,NA,N/A,262,Actual,"Applied Biology, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-07T10:47:31Z,2021-02-07T10:47:31Z,22
NCT04445272,"ClinicalTrials.gov processed this data on February 05, 2021",2020-06-13,NA,NA,2021-02-02,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-03,Actual,"May 22, 2020",Actual,2020-05-22,June 2020,2020-06-30,"December 23, 2020",Actual,2020-12-23,"December 23, 2020",Actual,2020-12-23,NA,Interventional,NA,,Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia,"A Multicentre, Open-label Clinical Trial to Evaluate the Effectiveness and Safety of Intravenous Tocilizumab for Treating Patients With COVID-19 Pneumonia: the BREATH-19 Study",Completed,NA,Phase 2,495,Actual,Fundacion SEIMC-GESIDA,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-07T10:47:32Z,2021-02-07T10:47:32Z,18
NCT04358926,"ClinicalTrials.gov processed this data on February 05, 2021",2020-04-21,NA,NA,2021-02-01,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-03,Actual,"April 30, 2020",Actual,2020-04-30,November 2020,2020-11-30,"November 1, 2020",Actual,2020-11-01,"October 15, 2020",Actual,2020-10-15,NA,Interventional,HBOTCOVID19,,Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Completed,NA,N/A,30,Actual,Assaf-Harofeh Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,Within 1 month of request,Specific requests,NA,Yes,Sharing upon specific requests will be considered,2021-02-07T10:48:40Z,2021-02-07T10:48:40Z,19
NCT04334434,"ClinicalTrials.gov processed this data on February 05, 2021",2020-04-02,NA,NA,2021-01-30,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-01-30,2021-02-03,Actual,"July 30, 2020",Actual,2020-07-30,January 2021,2021-01-31,"December 15, 2020",Actual,2020-12-15,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,,Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19),Investigation Of The Effectiveness Of The Telerehabilitation Applied To Individuals Over The Age Of 65 Who Experience Social Isolation At Houses Due To The Coronavirus (Covid-19) Pandemic,Completed,NA,N/A,30,Actual,Istanbul University-Cerrahpasa,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-07T10:48:51Z,2021-02-07T10:48:51Z,21
NCT04739410,"ClinicalTrials.gov processed this data on February 05, 2021",2021-02-02,NA,NA,2021-02-03,2021-02-03,2021-02-04,Actual,NA,NA,NA,NA,NA,NA,2021-02-03,2021-02-04,Actual,"May 1, 2020",Actual,2020-05-01,February 2021,2021-02-28,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,,Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,Completed,NA,Phase 4,50,Actual,FMH College of Medicine and Dentistry,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,as soon as i will have time to respond,NA,NA,Yes,"whatever is needed, will share if needed at any time",2021-02-08T10:27:28Z,2021-02-08T10:27:28Z,17
NCT04435522,"ClinicalTrials.gov processed this data on February 05, 2021",2020-06-15,NA,NA,2021-02-02,2020-06-15,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-04,Actual,"October 1, 2020",Actual,2020-10-01,June 2020,2020-06-30,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,,Maraviroc in Patients With Moderate and Severe COVID-19,Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2,Completed,NA,Phase 1,9,Actual,Rhode Island Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-08T10:33:15Z,2021-02-08T10:33:15Z,18
NCT04407130,"ClinicalTrials.gov processed this data on February 05, 2021",2020-05-17,NA,NA,2021-02-01,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-04,Actual,"June 16, 2020",Actual,2020-06-16,June 2020,2020-06-30,"November 20, 2020",Actual,2020-11-20,"October 30, 2020",Actual,2020-10-30,NA,Interventional,NA,,Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.,"Ivermectin and Doxycycline in Combination or Ivermectin Alone for the Treatment of Adult Bangladeshi Patients Hospitalized for COVID-19: a Randomised, Double-blind, Placebo-controlled Trial.",Completed,NA,Phase 2,72,Actual,"International Centre for Diarrhoeal Disease Research, Bangladesh",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-08T10:33:33Z,2021-02-08T10:33:33Z,19
NCT04402970,"ClinicalTrials.gov processed this data on February 08, 2021",2020-05-20,NA,NA,2021-02-04,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-02-04,2021-02-05,Actual,"June 19, 2020",Actual,2020-06-19,February 2021,2021-02-28,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,DORNASESARS2,,Dornase Alfa for ARDS in Patients With SARS-CoV-2,Inhaled Dornase Alfa for Treatment of ARDS in Patients With SARS-CoV-2,Completed,NA,Phase 3,10,Actual,University of Missouri-Columbia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-02-09T10:32:33Z,2021-02-09T10:32:33Z,16
NCT04746365,"ClinicalTrials.gov processed this data on February 12, 2021",2021-02-06,NA,NA,2021-02-08,2021-02-08,2021-02-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"December 6, 2020",Actual,2020-12-06,February 2021,2021-02-28,"February 6, 2021",Actual,2021-02-06,"January 31, 2021",Actual,2021-01-31,NA,Interventional,IRICT,,Ivermectin Role in Covid-19 Clinical Trial,"Ivermectin Role in Severe Covid-19 Treatment; a Double-blinded, Randomized Clinical Trial",Completed,NA,Phase 4,300,Actual,Elaraby Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-02-13T09:24:45Z,2021-02-13T09:24:45Z,12
NCT04745442,"ClinicalTrials.gov processed this data on February 12, 2021",2021-02-08,NA,NA,2021-02-08,2021-02-08,2021-02-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"April 27, 2020",Actual,2020-04-27,February 2021,2021-02-28,"January 15, 2021",Actual,2021-01-15,"December 20, 2020",Actual,2020-12-20,NA,Interventional,NA,,Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19,Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19,Completed,NA,Phase 2,48,Actual,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,The information will be provided after the results are published in a journal.,Upon request to uicec@imibic.org,NA,Yes,NA,2021-02-13T09:25:18Z,2021-02-13T09:25:18Z,12
NCT04668625,"ClinicalTrials.gov processed this data on February 12, 2021",2020-12-09,NA,NA,2021-02-05,2020-12-14,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-05,2021-02-08,Actual,"November 30, 2020",Actual,2020-11-30,January 2021,2021-01-31,"January 8, 2021",Actual,2021-01-08,"December 20, 2020",Actual,2020-12-20,NA,Interventional,NA,,"Risk of Infection of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), COVID-19, in a Massive Musical Show With Transmission Prevention Measures",Risk of Infection of SARS-CoV-2 in a Massive Musical Show With Transmission Prevention Measures: Randomized Study,Completed,NA,N/A,1000,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-13T09:30:17Z,2021-02-13T09:30:17Z,15
NCT04557241,"ClinicalTrials.gov processed this data on February 12, 2021",2020-09-16,NA,NA,2021-02-08,2020-09-17,2020-09-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"January 14, 2020",Actual,2020-01-14,February 2021,2021-02-28,"January 31, 2021",Actual,2021-01-31,"January 14, 2021",Actual,2021-01-14,NA,Interventional,NA,,Brief Informational Intervention for COVID-19 Misinformation Prophylaxis,Brief Informational Intervention for COVID-19 Misinformation Prophylaxis,Completed,NA,N/A,1017,Actual,Indiana University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Fully de-identified data will be made available along with the publication of the primary results paper from this study.,NA,NA,Yes,Fully de-identified data (full dataset) will be made available along with the publication of the primary results paper from this study.,2021-02-13T09:34:04Z,2021-02-13T09:34:04Z,12
NCT04547660,"ClinicalTrials.gov processed this data on February 12, 2021",2020-09-09,NA,NA,2021-02-08,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"July 16, 2020",Actual,2020-07-16,February 2021,2021-02-28,"January 7, 2021",Actual,2021-01-07,"January 7, 2021",Actual,2021-01-07,NA,Interventional,PLACOVID,,Convalescent Plasma for Severe COVID-19 Patients,"Convalescent Plasma for Severe COVID-19 Patients: a Randomized, Open-label, Phase 3 Trial",Completed,NA,Phase 3,160,Actual,Hospital de Clinicas de Porto Alegre,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-13T09:34:21Z,2021-02-13T09:34:21Z,12
NCT04534790,"ClinicalTrials.gov processed this data on February 12, 2021",2020-08-05,NA,NA,2021-02-08,2020-08-30,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"July 24, 2020",Actual,2020-07-24,February 2021,2021-02-28,"January 8, 2021",Actual,2021-01-08,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,,Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia,"Randomized Trial, Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia",Completed,NA,N/A,30,Actual,Instituto Mexicano del Seguro Social,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-02-13T09:34:46Z,2021-02-13T09:34:46Z,12
NCT04492475,"ClinicalTrials.gov processed this data on February 12, 2021",2020-07-28,NA,NA,2021-02-04,2020-07-28,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2021-02-04,2021-02-09,Actual,"August 5, 2020",Actual,2020-08-05,November 2020,2020-11-30,"December 21, 2020",Actual,2020-12-21,"December 21, 2020",Actual,2020-12-21,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial 3 (ACTT-3),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3)",Completed,NA,Phase 3,969,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-02-13T09:36:14Z,2021-02-13T09:36:14Z,16
NCT04385901,"ClinicalTrials.gov processed this data on February 12, 2021",2020-05-06,NA,NA,2021-02-04,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-04,2021-02-08,Actual,"May 19, 2020",Actual,2020-05-19,February 2021,2021-02-28,"September 19, 2020",Actual,2020-09-19,"September 19, 2020",Actual,2020-09-19,NA,Interventional,NA,,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Completed,NA,N/A,26,Actual,University of Missouri-Columbia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-13T09:39:09Z,2021-02-13T09:39:09Z,16
NCT04747158,"ClinicalTrials.gov processed this data on February 12, 2021",2021-01-27,NA,NA,2021-02-08,2021-02-08,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-10,Actual,"August 10, 2020",Actual,2020-08-10,February 2021,2021-02-28,"January 10, 2021",Actual,2021-01-10,"December 10, 2020",Actual,2020-12-10,NA,Interventional,TPCC,,COVID-19 Convalescent Plasma Therapy,COVID-19 Convalescent Plasma Therapy,Completed,NA,Phase 2/Phase 3,350,Actual,Universidad Nacional de AsunciÃ³n,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,The investigators will publish the results to compare data with other studies with COVID-19 convalescent plasma patients,2021-02-14T10:22:08Z,2021-02-14T10:22:08Z,12
NCT04747132,"ClinicalTrials.gov processed this data on February 12, 2021",2021-02-06,NA,NA,2021-02-08,2021-02-08,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-10,Actual,"July 20, 2020",Actual,2020-07-20,February 2021,2021-02-28,"November 16, 2020",Actual,2020-11-16,"October 20, 2020",Actual,2020-10-20,NA,Interventional,NA,,Effectiveness of a Telegeriatric Intervention in Older Adults During the Covid-19 Contingency,Effectiveness of a Telegeriatric Intervention in Older Adults During the Covid-19 Contingency,Completed,NA,N/A,110,Actual,"Universidad Iberoamericana A.C., Mexico",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-14T10:22:09Z,2021-02-14T10:22:09Z,12
NCT04337918,"ClinicalTrials.gov processed this data on February 12, 2021",2020-04-06,NA,NA,2021-02-08,2020-04-06,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-10,Actual,"May 8, 2020",Actual,2020-05-08,February 2021,2021-02-28,"February 2, 2021",Actual,2021-02-02,"January 31, 2021",Actual,2021-01-31,NA,Interventional,NOCOVID,,Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,"Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection",Completed,NA,Phase 2,143,Actual,Sanotize Research and Development corp.,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-14T10:30:58Z,2021-02-14T10:30:58Z,12
NCT04662671,"ClinicalTrials.gov processed this data on February 15, 2021",2020-12-09,NA,NA,2021-02-10,2020-12-09,2020-12-10,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"November 18, 2020",Actual,2020-11-18,February 2021,2021-02-28,"January 30, 2021",Actual,2021-01-30,"December 9, 2020",Actual,2020-12-09,NA,Interventional,NA,,"Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19","Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19",Completed,NA,Phase 1/Phase 2,31,Actual,KNOWBio Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-16T09:37:14Z,2021-02-16T09:37:14Z,10
NCT04621461,"ClinicalTrials.gov processed this data on February 15, 2021",2020-11-06,NA,NA,2021-02-08,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-11,Actual,"December 20, 2020",Actual,2020-12-20,February 2021,2021-02-28,"February 8, 2021",Actual,2021-02-08,"February 8, 2021",Actual,2021-02-08,NA,Interventional,NA,,Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting,"A Randomized, Placebo-Controlled Study Evaluating the Efficacy of Zinc for the Treatment of COVID-19 in the Outpatient Setting",Completed,NA,Phase 4,3,Actual,"St. Francis Hospital, New York",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-16T09:37:52Z,2021-02-16T09:37:52Z,12
NCT04749121,"ClinicalTrials.gov processed this data on February 15, 2021",2021-02-04,NA,NA,2021-02-09,2021-02-09,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-11,Actual,"April 1, 2020",Actual,2020-04-01,February 2021,2021-02-28,"February 5, 2021",Actual,2021-02-05,"February 5, 2021",Actual,2021-02-05,NA,Interventional,NA,,Ultraviolet Germicidal Irradiation on the New Silicone Half-Piece Elastometric Respirators,"Impact of Ultraviolet Germicidal Irradiation on the New Silicone Half-Piece Elastometric Respirators (VJR-NMU) Respirator Performances, Structural Integrity and Sterility During COVID -19 Pandemic:",Completed,NA,N/A,20,Actual,Bangkok Metropolitan Administration Medical College and Vajira Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,Plan to share in protocol.io,2021-02-16T09:35:11Z,2021-02-16T09:35:11Z,11
NCT04521309,"ClinicalTrials.gov processed this data on February 15, 2021",2020-05-07,NA,NA,2021-02-09,2020-08-19,2020-08-20,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-12,Actual,"June 19, 2020",Actual,2020-06-19,February 2020,2020-02-29,"February 8, 2021",Actual,2021-02-08,"January 26, 2021",Actual,2021-01-26,NA,Interventional,NA,,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Antibodies Based Intravenous Immunoglobulin (IVIG) Therapy for Severe and Critically Ill COVID-19 Patients,Completed,NA,Phase 1/Phase 2,50,Actual,Dow University of Health Sciences,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-16T09:39:57Z,2021-02-16T09:39:57Z,11
NCT04494984,"ClinicalTrials.gov processed this data on February 15, 2021",2020-07-29,NA,NA,2021-02-09,2020-07-30,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-11,Actual,"July 27, 2020",Actual,2020-07-27,February 2021,2021-02-28,"December 30, 2020",Actual,2020-12-30,"November 23, 2020",Actual,2020-11-23,NA,Interventional,NA,,"A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.","A Stage 2/3, Adaptive, Randomized, Controlled, Double-blind Study to Investigate the Pharmacokinetics, Efficacy and Safety of the Hyperimmune Equine Serum (INM005) in Adult Patients With Moderate to Severe Confirmed SARS-CoV2 Disease.",Completed,NA,Phase 2/Phase 3,242,Actual,Inmunova S.A.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-16T09:40:16Z,2021-02-16T09:40:16Z,11
NCT04389294,"ClinicalTrials.gov processed this data on February 15, 2021",2020-05-08,NA,NA,2021-02-10,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"May 5, 2020",Actual,2020-05-05,February 2021,2021-02-28,"September 4, 2020",Actual,2020-09-04,"June 16, 2020",Actual,2020-06-16,NA,Interventional,NA,,HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists,Hospital for Special Surgery COVID-19 Antibody Serology Among Anesthesiologists and Surgeons 2020,Completed,NA,N/A,143,Actual,"Hospital for Special Surgery, New York",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-16T09:41:46Z,2021-02-16T09:41:46Z,10
NCT04362813,"ClinicalTrials.gov processed this data on February 15, 2021",2020-04-24,NA,2021-02-08,2021-02-09,2020-04-24,2020-04-27,Actual,NA,NA,NA,2021-02-09,2021-02-11,Actual,2021-02-09,2021-02-11,Actual,"April 30, 2020",Actual,2020-04-30,February 2021,2021-02-28,"December 22, 2020",Actual,2020-12-22,"September 16, 2020",Actual,2020-09-16,NA,Interventional,CAN-COVID,,Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,"Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)",Completed,NA,Phase 3,451,Actual,Novartis,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2021-02-16T09:42:11Z,2021-02-16T09:42:11Z,11
NCT04357808,"ClinicalTrials.gov processed this data on February 15, 2021",2020-04-14,NA,NA,2021-02-10,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"April 13, 2020",Actual,2020-04-13,February 2021,2021-02-28,"December 4, 2020",Actual,2020-12-04,"November 30, 2020",Actual,2020-11-30,NA,Interventional,SARCOVID,,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),Randomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 Infection,Completed,NA,Phase 2,30,Actual,FundaciÃ³n de InvestigaciÃ³n BiomÃ©dica - Hospital Universitario de La Princesa,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-02-16T09:42:18Z,2021-02-16T09:42:18Z,10
NCT04352959,"ClinicalTrials.gov processed this data on February 15, 2021",2020-04-15,NA,NA,2021-02-10,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"April 27, 2020",Actual,2020-04-27,February 2021,2021-02-28,"December 11, 2020",Actual,2020-12-11,"December 11, 2020",Actual,2020-12-11,NA,Interventional,BBCovid,,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,"COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses: Double-blind, Randomized, Placebo-controlled Clinical Study",Completed,NA,N/A,176,Actual,Claude Bernard University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-16T09:42:21Z,2021-02-16T09:42:21Z,10
NCT04317040,"ClinicalTrials.gov processed this data on February 15, 2021",2020-03-19,NA,NA,2021-02-10,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"April 8, 2020",Actual,2020-04-08,February 2021,2021-02-28,"January 30, 2021",Actual,2021-01-30,"October 23, 2020",Actual,2020-10-23,NA,Interventional,SAC-COVID,,CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment,"A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment",Completed,NA,Phase 3,243,Actual,"OncoImmune, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-16T09:42:41Z,2021-02-16T09:42:41Z,10
NCT04331600,"ClinicalTrials.gov processed this data on February 15, 2021",2020-03-30,NA,NA,2021-02-10,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,"December 17, 2020",Actual,2020-12-17,"December 17, 2020",Actual,2020-12-17,NA,Interventional,NA,,Chloroquine as Antiviral Treatment in Coronavirus Infection 2020,"Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications",Completed,NA,Phase 4,16,Actual,Wroclaw Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-16T09:42:34Z,2021-02-16T09:42:34Z,10
NCT04750317,"ClinicalTrials.gov processed this data on February 18, 2021",2021-02-10,NA,NA,2021-02-11,2021-02-10,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-02-11,2021-02-15,Actual,"May 11, 2020",Actual,2020-05-11,February 2021,2021-02-28,"September 1, 2020",Actual,2020-09-01,"August 1, 2020",Actual,2020-08-01,NA,Interventional,TOFA-COV-2,,Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia,Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia,Completed,NA,Phase 2,414,Actual,I.M. Sechenov First Moscow State Medical University,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-19T11:18:55Z,2021-02-19T11:18:55Z,9
NCT04322396,"ClinicalTrials.gov processed this data on February 18, 2021",2020-03-23,NA,NA,2021-02-10,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-15,Actual,"April 6, 2020",Actual,2020-04-06,February 2021,2021-02-28,"February 2, 2021",Actual,2021-02-02,"February 2, 2021",Actual,2021-02-02,NA,Interventional,ProPAC-COVID,,Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,"Proactive Protection With Azithromycin and Hydroxychloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19",Completed,NA,Phase 2,117,Actual,"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-02-19T11:28:49Z,2021-02-19T11:28:49Z,10
NCT04312009,"ClinicalTrials.gov processed this data on February 18, 2021",2020-03-13,NA,NA,2021-02-12,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-15,Actual,"April 13, 2020",Actual,2020-04-13,February 2021,2021-02-28,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization,Completed,NA,Phase 2,200,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-19T11:28:58Z,2021-02-19T11:28:58Z,8
NCT04311177,"ClinicalTrials.gov processed this data on February 18, 2021",2020-03-13,NA,NA,2021-02-12,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-15,Actual,"April 9, 2020",Actual,2020-04-09,February 2021,2021-02-28,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization,Completed,NA,Phase 2,580,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-19T11:29:01Z,2021-02-19T11:29:01Z,8
NCT04758286,"ClinicalTrials.gov processed this data on February 18, 2021",2021-02-11,NA,NA,2021-02-16,2021-02-16,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-17,Actual,"July 1, 2020",Actual,2020-07-01,February 2021,2021-02-28,"February 11, 2021",Actual,2021-02-11,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,,Anesthetic & Surgical Protocol for Emergency Surgeries During the Era of COVID-19,Protocol for Anesthesia for Emergency Surgery,Completed,NA,N/A,209,Actual,Benha University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,after publishing,email,NA,Yes,The study protocol may be shared,2021-02-20T10:52:50Z,2021-02-20T10:52:50Z,4
NCT04609462,"ClinicalTrials.gov processed this data on February 18, 2021",2020-09-24,NA,NA,2021-02-17,2020-10-28,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Estimate,"August 11, 2020",Actual,2020-08-11,February 2021,2021-02-28,"February 10, 2021",Actual,2021-02-10,"January 13, 2021",Actual,2021-01-13,NA,Interventional,HiFlo-COVID,,High-Flow Nasal Cannula in Severe COVID-19 With Acute Hypoxemic Respiratory Failure.,A Trial of High-Flow Nasal Cannula vs. Conventional Oxygen Therapy in Patients With SARS-CoV-2-Related Acute Respiratory Failure: the HiFlo-COVID Trial.,Completed,NA,N/A,199,Actual,Fundacion Clinica Valle del Lili,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-20T10:57:48Z,2021-02-20T10:57:48Z,3
NCT04517422,"ClinicalTrials.gov processed this data on February 18, 2021",2020-08-16,NA,NA,2021-02-14,2020-08-16,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-02-14,2021-02-17,Actual,"August 19, 2020",Actual,2020-08-19,February 2021,2021-02-28,"February 2, 2021",Actual,2021-02-02,"February 2, 2021",Actual,2021-02-02,NA,Interventional,NA,,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,Efficacy and Safety of Lactobacillus Plantarum and Pediococcus Acidilactici as Co-adjuvant Therapy for Reducing the Risk of Severe Disease in Adults With SARS-CoV-2 and Its Modulation of the Fecal Microbiota: A Randomized Clinical Trial,Completed,NA,N/A,300,Actual,"AB Biotics, SA",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-20T10:59:21Z,2021-02-20T10:59:21Z,6
NCT04473898,"ClinicalTrials.gov processed this data on February 18, 2021",2020-07-14,NA,NA,2021-02-17,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Estimate,"June 19, 2020",Actual,2020-06-19,July 2020,2020-07-31,"February 17, 2021",Actual,2021-02-17,"October 19, 2020",Actual,2020-10-19,NA,Interventional,NA,,Telerehabilitation After Coronavirus,Telerehabilitation After Covid-19: Effectiveness of Respiratory and Aerobic Training,Completed,NA,N/A,35,Actual,KTO Karatay University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-20T10:59:55Z,2021-02-20T10:59:55Z,3
NCT04425538,"ClinicalTrials.gov processed this data on February 18, 2021",2020-06-08,NA,NA,2021-02-17,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Estimate,"June 1, 2020",Actual,2020-06-01,February 2021,2021-02-28,"January 22, 2021",Actual,2021-01-22,"January 22, 2021",Actual,2021-01-22,NA,Interventional,NA,,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,Completed,NA,Phase 2,17,Actual,Tufts Medical Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-20T11:00:56Z,2021-02-20T11:00:56Z,3
NCT04386616,"ClinicalTrials.gov processed this data on February 18, 2021",2020-05-11,NA,NA,2021-02-16,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-17,Actual,"June 2, 2020",Actual,2020-06-02,February 2021,2021-02-28,"February 12, 2021",Actual,2021-02-12,"January 2, 2021",Actual,2021-01-02,NA,Interventional,COVASTIL,,A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia,"A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MSTT1041A or UTTR1147A in Patients With Severe COVID-19 Pneumonia",Completed,NA,Phase 2,410,Actual,"Genentech, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).
For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2021-02-20T11:01:38Z,2021-02-20T11:01:38Z,4
NCT04377789,"ClinicalTrials.gov processed this data on February 18, 2021",2020-05-01,NA,NA,2021-02-17,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Estimate,"March 20, 2020",Actual,2020-03-20,February 2021,2021-02-28,"August 31, 2020",Actual,2020-08-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,,Effect of Quercetin on Prophylaxis and Treatment of COVID-19,The Possible Effect of Quercetin on Prophylaxis and Treatment of COVID-19,Completed,NA,N/A,447,Actual,Kanuni Sultan Suleyman Training and Research Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-02-20T11:01:48Z,2021-02-20T11:01:48Z,3
NCT04342728,"ClinicalTrials.gov processed this data on February 18, 2021",2020-04-08,NA,NA,2021-02-12,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-16,Actual,"April 8, 2020",Actual,2020-04-08,February 2021,2021-02-28,"February 11, 2021",Actual,2021-02-11,"December 30, 2020",Actual,2020-12-30,NA,Interventional,COVIDAtoZ,,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,"Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study",Completed,NA,N/A,214,Actual,The Cleveland Clinic,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-02-20T11:02:13Z,2021-02-20T11:02:13Z,8
NCT04331834,"ClinicalTrials.gov processed this data on February 18, 2021",2020-04-01,NA,NA,2021-02-15,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-15,2021-02-16,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"December 31, 2020",Actual,2020-12-31,"June 25, 2020",Actual,2020-06-25,NA,Interventional,PrEP_COVID,,Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic,"Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Multicentre, Double-Blinded Randomized Controlled Trial",Completed,NA,Phase 3,275,Actual,Barcelona Institute for Global Health,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-02-20T11:02:22Z,2021-02-20T11:02:22Z,5
NCT04331366,"ClinicalTrials.gov processed this data on February 18, 2021",2020-03-31,2021-02-05,NA,2021-02-16,2020-03-31,2020-04-02,Actual,2021-02-05,2021-02-10,Actual,NA,NA,NA,2021-02-16,2021-02-18,Estimate,"April 8, 2020",Actual,2020-04-08,February 2021,2021-02-28,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,NA,Interventional,GO2 PEEP,,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Completed,NA,N/A,2,Actual,Emory University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,NA,NA,,NA,NA,NA,No,NA,2021-02-20T11:02:24Z,2021-02-20T11:02:24Z,4
